[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1693
1. Bruna Esteban M, Montalvá Orón E, López Delgado A, Galindo Jara P, Vázquez Prado A, Fabra Ramis R: [Gastric adenocarcinoma in Zinsser-Cole-Engman syndrome]. Cir Esp; 2006 Sep;80(3):176-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastric adenocarcinoma in Zinsser-Cole-Engman syndrome].
  • [Transliterated title] Adenocarcinoma gástrico en el síndrome de Zinsser-Cole-Engman.
  • We report the case of a 37-year-old man with this syndrome who was diagnosed with gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / etiology. Dyskeratosis Congenita / complications. Stomach Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16956556.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


2. Burbano RR, Assumpção PP, Leal MF, Calcagno DQ, Guimarães AC, Khayat AS, Takeno SS, Chen ES, De Arruda Cardoso Smith M: C-MYC locus amplification as metastasis predictor in intestinal-type gastric adenocarcinomas: CGH study in Brazil. Anticancer Res; 2006 Jul-Aug;26(4B):2909-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] C-MYC locus amplification as metastasis predictor in intestinal-type gastric adenocarcinomas: CGH study in Brazil.
  • BACKGROUND: The genetic events involved in gastric cancer, the third most frequent cancer in the world with a high incidence in Pard State, Brazil, remain largely unknown.
  • MATERIALS AND METHODS: Twenty-one primary gastric adenocarcinomas were investigated by comparative genomic hybridization (CGH) and the relationships between genomic abnormalities and histopathological features were evaluated.
  • CONCLUSION: C-MYC locus amplification may be predictor of aggressiveness in intestinal-type gastric cancer, playing an important role in its development and progression.
  • Gastric adenocarcinomas of differing histopathological features were associated with distinct genetic alterations, supporting the hypothesis that they evolve through distinct genetic pathways.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Genes, myc. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16886612.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


3. Ohnishi N, Yuasa H, Tanaka S, Sawa H, Miura M, Matsui A, Higashi H, Musashi M, Iwabuchi K, Suzuki M, Yamada G, Azuma T, Hatakeyama M: Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse. Proc Natl Acad Sci U S A; 2008 Jan 22;105(3):1003-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Infection with cagA-positive Helicobacter pylori is associated with gastric adenocarcinoma and gastric mucosa-associated lymphoid tissue (MALT) lymphoma of B cell origin.
  • The cagA-encoded CagA protein is delivered into gastric epithelial cells via the bacterial type IV secretion system and, upon tyrosine phosphorylation by Src family kinases, specifically binds to and aberrantly activates SHP-2 tyrosine phosphatase, a bona fide oncoprotein in human malignancies.
  • Here, we generated transgenic mice expressing wild-type or phosphorylation-resistant CagA throughout the body or predominantly in the stomach.
  • Wild-type CagA transgenic mice showed gastric epithelial hyperplasia and some of the mice developed gastric polyps and adenocarcinomas of the stomach and small intestine.

  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14559-64 [10588744.001]
  • [Cites] Gastroenterology. 2005 May;128(5):1229-42 [15887107.001]
  • [Cites] Science. 2002 Jan 25;295(5555):683-6 [11743164.001]
  • [Cites] J Biol Chem. 2002 Mar 1;277(9):6775-8 [11788577.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):28-37 [11902583.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14428-33 [12391297.001]
  • [Cites] Mol Cell. 2002 Oct;10(4):745-55 [12419219.001]
  • [Cites] J Cell Biol. 2003 Apr 28;161(2):249-55 [12719469.001]
  • [Cites] Bioessays. 2003 Jun;25(6):542-53 [12766944.001]
  • [Cites] Nat Genet. 2003 Jun;34(2):148-50 [12717436.001]
  • [Cites] J Biol Chem. 2004 Apr 23;279(17):17205-16 [14963045.001]
  • [Cites] Nat Med. 2004 Aug;10(8):849-57 [15273746.001]
  • [Cites] Blood. 2005 Jul 1;106(1):311-7 [15761018.001]
  • [Cites] Eur J Med Genet. 2005 Apr-Jun;48(2):81-96 [16053901.001]
  • [Cites] J Exp Med. 2005 Nov 7;202(9):1235-47 [16275761.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):261-76 [16354697.001]
  • [Cites] Gastroenterology. 2006 Apr;130(4):1181-90 [16618412.001]
  • [Cites] Annu Rev Biochem. 2006;75:137-63 [16756488.001]
  • [Cites] Nature. 2007 May 17;447(7142):330-3 [17507984.001]
  • [Cites] Oncogene. 2007 May 24;26(24):3462-72 [17160020.001]
  • [Cites] Oncogene. 2007 Jul 12;26(32):4617-26 [17237808.001]
  • [Cites] Genes Dev. 2004 Aug 15;18(16):1909-25 [15314019.001]
  • [Cites] Nat Rev Cancer. 2004 Sep;4(9):688-94 [15343275.001]
  • [Cites] Cancer Res. 1992 Dec 15;52(24):6735-40 [1458460.001]
  • [Cites] J Biol Chem. 1993 Dec 15;268(35):26559-70 [8253786.001]
  • [Cites] N Engl J Med. 1994 May 5;330(18):1267-71 [8145781.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jan 3;92(1):160-4 [7816809.001]
  • [Cites] Cancer Res. 1995 May 15;55(10):2111-5 [7743510.001]
  • [Cites] J Natl Cancer Inst. 1995 Dec 6;87(23):1777-80 [7473834.001]
  • [Cites] Am J Clin Pathol. 1996 Nov;106(5):670-5 [8929480.001]
  • [Cites] Trends Genet. 1996 May;12(5):171-5 [8984731.001]
  • [Cites] J Pharmacol Exp Ther. 1997 Jan;280(1):225-31 [8996200.001]
  • [Cites] Gut. 1997 Mar;40(3):297-301 [9135515.001]
  • [Cites] Mol Cell Biol. 1997 Sep;17(9):5499-507 [9271425.001]
  • [Cites] Am J Gastroenterol. 1998 Mar;93(3):375-9 [9517643.001]
  • [Cites] Gastroenterology. 1998 Sep;115(3):642-8 [9721161.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4255-9 [9766647.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8816-20 [15604238.001]
  • [Cites] Blood. 2001 Feb 15;97(4):911-4 [11159516.001]
  • (PMID = 18192401.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / Bacterial Proteins; 0 / cagA protein, Helicobacter pylori; 21820-51-9 / Phosphotyrosine
  • [Other-IDs] NLM/ PMC2242726
  •  go-up   go-down


Advertisement
4. Ramírez Ramos A, Sánchez Sánchez R: [Helicobacter pylori and gastric cancer]. Rev Gastroenterol Peru; 2008 Jul-Sep;28(3):258-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Helicobacter pylori and gastric cancer].
  • Since its discovery and identification in gastric tissue by Marshall and Warren in 1983, our knowledge about the effects of Helicobacter pylori infection has grown considerably.
  • Its role in the multifactorial pathology of peptic ulcer disease (gastrodudodenal ulcer disease), gastric adenocarcinoma, and MALT lymphoma is now widely accepted while its involvement in extraintestinal disease is still controversial.The correlation between the colonization of the stomach by H. pylori and gastric lymphoma has been demonstrated in multiple studies.
  • Between 65 and 80% of distal gastric adenocarcinomas are attributed to H. pylori infection.
  • However, gastric carcinogenesis cannot be explained by H. pylori infection alone.
  • Among those individuals infected by this bacteria, only a small percentage (2-5%) ever develops gastric cancer, the majority exhibit benign lesions.
  • In this article, we conduct a review of the widely accepted theories regarding gastric cancer, Helicobacter pylori, the correlations and enigmas between them, the reported geographical variations, and the various proposed hypotheses on the carcinogenic mechanism of Helicobacter pylori.
  • [MeSH-major] Adenocarcinoma / etiology. Helicobacter Infections / complications. Helicobacter pylori. Lymphoma / etiology. Lymphoma, B-Cell, Marginal Zone / etiology. Stomach Neoplasms / etiology
  • [MeSH-minor] Diet. Humans. Risk Factors. Socioeconomic Factors. Stomach / microbiology. Virulence

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18958142.001).
  • [ISSN] 1022-5129
  • [Journal-full-title] Revista de gastroenterología del Perú : órgano oficial de la Sociedad de Gastroenterología del Perú
  • [ISO-abbreviation] Rev Gastroenterol Peru
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Peru
  • [Number-of-references] 29
  •  go-up   go-down


5. Jang TJ: The number of Foxp3-positive regulatory T cells is increased in Helicobacter pylori gastritis and gastric cancer. Pathol Res Pract; 2010 Jan 15;206(1):34-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The number of Foxp3-positive regulatory T cells is increased in Helicobacter pylori gastritis and gastric cancer.
  • Persistent H. pylori-associated gastritis is closely associated with gastric carcinogenesis.
  • We investigated the number of Tregs in the context of H. pylori colonization in chronic gastritis, examined the relationship between it and histopathological findings and compared it with that of gastric dysplasia and adenocarcinoma.
  • This study was based on the analysis of gastric biopsy specimens from 126 cases of H. pylori-associated gastritis, 16 cases of H. pylori-negative gastritis, 17 cases of gastric dysplasia, and 25 cases of gastric adenocarcinoma.
  • It was significantly elevated in adenocarcinomas compared to chronic gastritis and gastric dysplasia.
  • In summary, the number of Tregs is increased in H. pylori-associated gastritis and gastric cancer.
  • [MeSH-major] Adenocarcinoma / immunology. Forkhead Transcription Factors / immunology. Gastritis / immunology. Helicobacter Infections / immunology. Helicobacter pylori / immunology. Stomach Neoplasms / immunology. T-Lymphocytes, Regulatory / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Analysis of Variance. Cell Count. Child. Female. Gastric Mucosa / immunology. Gastric Mucosa / pathology. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier GmbH. All rights reserved.
  • (PMID = 19819643.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors
  •  go-up   go-down


6. Sharma A, Nitharwal RG, Singh B, Dar A, Dasgupta S, Dhar SK: Helicobacter pylori single-stranded DNA binding protein--functional characterization and modulation of H. pylori DnaB helicase activity. FEBS J; 2009 Jan;276(2):519-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Helicobacter pylori, an important bacterial pathogen, causes gastric ulcer and gastric adenocarcinoma in humans.


7. Azem J, Svennerholm AM, Lundin BS: B cells pulsed with Helicobacter pylori antigen efficiently activate memory CD8+ T cells from H. pylori-infected individuals. Clin Immunol; 2006 Feb-Mar;118(2-3):284-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Helicobacter pylori infection causes chronic gastritis that may progress to peptic ulcers or gastric adenocarcinoma and thereby cause major world-wide health problems.
  • We further show that the majority of CD8+ T cells in H. pylori-infected gastric mucosa are memory cells, and that memory CD8+ T cells sorted from peripheral blood of H. pylori-infected individuals respond 15-fold more to H. pylori urease compared to memory cells from uninfected subjects.
  • [MeSH-minor] Adult. Cell Proliferation. Cells, Cultured. Gastric Mucosa / immunology. Gastric Mucosa / microbiology. Humans. Middle Aged. Monocytes / immunology

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16324887.001).
  • [ISSN] 1521-6616
  • [Journal-full-title] Clinical immunology (Orlando, Fla.)
  • [ISO-abbreviation] Clin. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Bacterial
  •  go-up   go-down


8. Khan AZ, Miles WF, Singh KK: Initial experience with laparoscopic bypass for upper gastrointestinal malignancy: a new option for palliation of patients with advanced upper gastrointestinal tumors. J Laparoendosc Adv Surg Tech A; 2005 Aug;15(4):374-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Various interventions have been described for the palliation of biliary and gastric outlet obstruction including open surgery, endoscopic and transparietal stent placement.
  • PATIENTS AND METHODS: Between August 2000 and April 2002 laparoscopic gastric and biliary bypass concurrently or alone was attempted in 19 consecutive patients with unresectable carcinoma of the head of the pancreas, adenocarcinoma of the stomach, cholangiocarcinoma of the distal common bile duct, or adenocarcinoma of the duodenum.

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16108739.001).
  • [ISSN] 1092-6429
  • [Journal-full-title] Journal of laparoendoscopic & advanced surgical techniques. Part A
  • [ISO-abbreviation] J Laparoendosc Adv Surg Tech A
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Kouraklis G, Katsoulis IE, Theocharis S, Tsourouflis G, Xipolitas N, Glinavou A, Sioka C, Kostakis A: Does the expression of cyclin E, pRb, and p21 correlate with prognosis in gastric adenocarcinoma? Dig Dis Sci; 2009 May;54(5):1015-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does the expression of cyclin E, pRb, and p21 correlate with prognosis in gastric adenocarcinoma?
  • The aim of this study was to investigate whether cyclin E, pRb, and p21 can be used as prognostic indicators in gastric cancer.
  • MATERIAL AND METHODS: Fifty-six patients with gastric adenocarcinoma, who underwent curative resection, constituted the group of our study.
  • Positive pRb immunostaining was found in 24 (42.9%) cases and it was associated with the absence of Helicobacter pylori (P=0.044), whereas positive p21 immunostaining was found in 21 tumors (37.5%) and it was associated with less depth of gastric wall infiltration (P=0.001), the absence of lymphatic (P=0.019) and vascular infiltration (P=0.024), and the absence of liver metastasis (P=0.044).
  • CONCLUSION: The expression of cyclin E could not predict the survival in this series of patients with gastric cancer, whereas the expression of pRb and p21 was associated with a favorable prognosis.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Cyclin E / analysis. Cyclin-Dependent Kinase Inhibitor p21 / analysis. Gastrectomy. Oncogene Proteins / analysis. Retinoblastoma Protein / analysis. Stomach Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 1999 Apr;25(2):157-63 [10218458.001]
  • [Cites] Ann Surg. 1997 Jul;226(1):35-42 [9242335.001]
  • [Cites] Cancer Lett. 2000 May 29;153(1-2):129-36 [10779641.001]
  • [Cites] Br J Cancer. 1997;75(11):1617-20 [9184177.001]
  • [Cites] Hum Pathol. 2003 Dec;34(12):1276-82 [14691913.001]
  • [Cites] Cancer Lett. 2000 Feb 1;148(2):181-8 [10695995.001]
  • [Cites] Anticancer Res. 1999 Sep-Oct;19(5B):4215-20 [10628377.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1821-8 [7997877.001]
  • [Cites] Int J Oncol. 2000 Nov;17(5):963-9 [11029499.001]
  • [Cites] Kurume Med J. 2000;47(3):199-203 [11059220.001]
  • [Cites] J Exp Clin Cancer Res. 2005 Sep;24(3):405-14 [16270527.001]
  • [Cites] J Korean Med Sci. 1998 Oct;13(5):513-8 [9811181.001]
  • [Cites] J Pathol. 1999 Oct;189(2):186-93 [10547573.001]
  • [Cites] Jpn J Cancer Res. 1997 Jul;88(7):625-9 [9310133.001]
  • [Cites] Korean J Intern Med. 2005 Mar;20(1):1-7 [15906946.001]
  • [Cites] Jpn J Cancer Res. 1995 Jul;86(7):617-21 [7559076.001]
  • [Cites] Eur J Surg Oncol. 2000 Feb;26(1):39-43 [10718178.001]
  • [Cites] Oncology. 2002;63(4):353-61 [12417790.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1447-53 [15746045.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):585-94 [10666388.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1672-7 [8939849.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1238-43 [9529014.001]
  • [Cites] Gastric Cancer. 1998 Mar 1;1(2):160-165 [11957061.001]
  • [Cites] Histopathology. 2003 Jan;42(1):66-9 [12493027.001]
  • [Cites] Cancer. 1997 Jun 1;79(11):2067-72 [9179052.001]
  • [Cites] J Exp Ther Oncol. 1996 Mar;1(2):88-94 [9414392.001]
  • [Cites] Chin Med J (Engl). 2003 Jan;116(1):20-3 [12667381.001]
  • [Cites] Scand J Gastroenterol. 2001 Sep;36(9):975-80 [11521990.001]
  • (PMID = 19058005.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CCNE1 protein, human; 0 / CDKN1A protein, human; 0 / Cyclin E; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Oncogene Proteins; 0 / Retinoblastoma Protein
  •  go-up   go-down


10. Pazos Y, Alvarez CJ, Camiña JP, Casanueva FF: Lysophosphatidic acid inhibits ghrelin secretion in the human gastric adenocarcinoma AGS cell line: role of mitogenic activated protein kinase signaling pathway. FEBS J; 2007 Nov;274(21):5714-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lysophosphatidic acid inhibits ghrelin secretion in the human gastric adenocarcinoma AGS cell line: role of mitogenic activated protein kinase signaling pathway.
  • The present study analyzes the molecular steps involved in the full lysophosphatidic acid (LPA) receptor-mediated activation of the mitogenic extracellular signal-regulated kinase (ERK) pathway and its consequent role as an inhibitor of ghrelin secretion in the gastric adenocarcinoma cell line AGS.
  • Finally, a correlation was observed between the mitogenic effects of LPA and ghrelin secretion in the human gastric adenocarcinoma cell line AGS.
  • [MeSH-major] Adenocarcinoma / metabolism. Ghrelin / metabolism. Lysophospholipids / pharmacology. MAP Kinase Signaling System. Stomach Neoplasms / metabolism


11. Di Costanzo F, Gasperoni S, Manzione L, Bisagni G, Labianca R, Bravi S, Cortesi E, Carlini P, Bracci R, Tomao S, Messerini L, Arcangeli A, Torri V, Bilancia D, Floriani I, Tonato M, Italian Oncology Group for Cancer Research, Dinota A, Strafiuso G, Corgna E, Porrozzi S, Boni C, Rondini E, Giunta A, Monzio Compagnoni B, Biagioni F, Cesari M, Fornarini G, Nelli F, Carboni M, Cognetti F, Enzo MR, Piga A, Romiti A, Olivetti A, Masoni L, De Stefanis M, Dalla Mola A, Camera S, Recchia F, De Filippis S, Scipioni L, Zironi S, Luppi G, Italia M, Banducci S, Pisani Leretti A, Massidda B, Ionta MT, Nicolosi A, Canaletti R, Biscottini B, Grigniani F, Di Costanzo F, Rovei R, Croce E, Carroccio R, Gilli G, Cavalli C, Olgiati A, Pandolfi U, Rossetti R, Natalini G, Foa P, Oldani S, Bruno L, Cascinu S, Catalano G, Catalano V, Lungarotti F, Farris A, Sarobba MG, Trignano M, Muscogiuri A, Francavilla F, Figoli F, Leoni M, Papiani G, Orselli G, Antimi M, Bellini V, Cabassi A, Contu A, Pazzola A, Frignano M, Lastraioli E, Saggese M, Bianchini D, Antonuzzo L, Mela M, Camisa R: Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst; 2008 Mar 19;100(6):388-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.
  • BACKGROUND: Complete surgical resection of gastric cancer is potentially curative, but long-term survival is poor.
  • METHODS: Patients with histologically proven adenocarcinoma of the stomach of stages IB, II, IIIA and B, or IV (T4N2M0) and treated with potentially curative surgery were randomly assigned to follow-up alone or to intravenous treatment with four cycles (repeated every 21 days) of PELF (cisplatin [40 mg/m(2), on days 1 and 5], epirubicin [30 mg/m(2), days 1 and 5], L-leucovorin [100 mg/m(2), days 1-4], and 5-fluorouracil [300 mg/m(2), days 1-4] in a hospital setting.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Gastrectomy. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2008 Mar 19;100(6):376-7 [18334705.001]
  • (PMID = 18334706.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; FLEP protocol
  •  go-up   go-down


12. Wang R, Ciren YJ, Yang JL, Zhang B, Chen JP, Tang CW: [Celecoxib inhibits gastric adenocarcinoma growth via inducing expression of human nonsteroidal anti-inflammatory drug activated gene]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Nov;40(6):1029-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Celecoxib inhibits gastric adenocarcinoma growth via inducing expression of human nonsteroidal anti-inflammatory drug activated gene].
  • OBJECTIVE: To investigate the effect of cyclooxygenase2 inhibitor celecoxib on the suppression of human gastric cancer (GC) growth and the induction of nonsteroidal anti-inflammatory drug activated gene (NAG-1) expression.
  • [MeSH-major] Adenocarcinoma / drug therapy. Cyclooxygenase 2 Inhibitors / therapeutic use. Growth Differentiation Factor 15 / metabolism. Pyrazoles / therapeutic use. Stomach Neoplasms / drug therapy. Sulfonamides / therapeutic use

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CELECOXIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20067113.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / GDF15 protein, human; 0 / Growth Differentiation Factor 15; 0 / Pyrazoles; 0 / RNA, Messenger; 0 / Sulfonamides; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


13. Maev IV, Mel'nikova EV, Kashin SV, Nadezhin AS, Kriukova TV: [Serologic screening for preneoplastic pathology and early stomach cancer]. Klin Med (Mosk); 2008;86(11):43-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Serologic screening for preneoplastic pathology and early stomach cancer].
  • Cancer of stomach is currently regarded as the final result of a staged multifactor process during which the microenvironment affects cells and causes their changes.
  • Adenocarcinoma of stomach develops via stages of gastritis, precancerous changes, and cancer.
  • The possibility to prevent cancer ensues from the potential irreversibility of premalignant processes in gastric mucosa, in the first place its atrophy; hence, the importance of its early diagnosis.
  • "GastroPanel", a new serological test for the diagnosis of gastric pathology provides information about histological and functional characteristics of gastric mucosa in the antral and fundal regions of the stomach.
  • Our results demonstrate high diagnostic efficiency of "GastroPanel" as a screening technique for atrophic gastritis and assessment of stomach cancer risk.
  • [MeSH-major] Helicobacter Infections / immunology. Helicobacter Infections / microbiology. Helicobacter pylori / isolation & purification. Mass Screening / methods. Stomach Neoplasms / blood. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19177794.001).
  • [ISSN] 0023-2149
  • [Journal-full-title] Klinicheskaia meditsina
  • [ISO-abbreviation] Klin Med (Mosk)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Gastrins; 0 / Peptide Fragments; 60748-06-3 / gastrin 17; 75903-15-0 / pepsinogen (1-12); 9001-10-9 / Pepsinogen A
  •  go-up   go-down


14. Giglio P, Weinberg JS, Forman AD, Wolff R, Groves MD: Neoplastic meningitis in patients with adenocarcinoma of the gastrointestinal tract. Cancer; 2005 Jun 1;103(11):2355-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoplastic meningitis in patients with adenocarcinoma of the gastrointestinal tract.
  • RESULTS: The patient population was composed of patients with gastric adenocarcinoma (n = 8 patients), esophageal adenocarcinoma (n = 7 patients), colon and/or rectal adenocarcinoma (n = 5 patients), and pancreatic adenocarcinoma (n = 1 patient).
  • The median overall survival after the initial diagnosis of adenocarcinoma was 55 weeks (range, 8-884 wks), and the median survival after the diagnosis of NM was 7 weeks (range, 0-64 wks).
  • No factors identified had an impact on outcome, including symptoms, physical findings at diagnosis, imaging characteristics, or cerebrospinal fluid findings.
  • CONCLUSIONS: Patients with NM from GI tract adenocarcinomas universally had poor outcomes.
  • [MeSH-major] Adenocarcinoma / secondary. Gastrointestinal Neoplasms / pathology. Meningeal Neoplasms / secondary

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15856426.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


15. Tatemichi M, Sawa T, Gilibert I, Tazawa H, Katoh T, Ohshima H: Increased risk of intestinal type of gastric adenocarcinoma in Japanese women associated with long forms of CCTTT pentanucleotide repeat in the inducible nitric oxide synthase promoter. Cancer Lett; 2005 Jan 20;217(2):197-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased risk of intestinal type of gastric adenocarcinoma in Japanese women associated with long forms of CCTTT pentanucleotide repeat in the inducible nitric oxide synthase promoter.
  • Tandem repeat number polymorphism of a CCTTT pentanucleotide in the promoter region of the inducible nitric oxide synthase gene (iNOS) and a polymorphism of the interleukin-1beta (IL-1B) promoter at position -31 were analyzed in DNA samples from 181 Japanese control subjects and 158 gastric cancer patients, including 96 intestinal type and 62 diffuse type.
  • An association between the intestinal type of gastric adenocarcinoma and higher promoter activity of the iNOS gene was found in women, especially those having higher promoter activity of the IL-1B gene and without a history of smoking.
  • Our results imply that chronic inflammation caused by excess nitric oxide generated by iNOS contributes to Helicobacter pylori-induced gastric cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Microsatellite Repeats / genetics. Nitric Oxide Synthase / genetics. Promoter Regions, Genetic / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15617837.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Interleukin-1; EC 1.14.13.39 / NOS2 protein, human; EC 1.14.13.39 / Nitric Oxide Synthase; EC 1.14.13.39 / Nitric Oxide Synthase Type II
  •  go-up   go-down


16. Ibáñez FJ, Azagra JS, Goergen M, Bordas JM, Almendral ML, Erro JM: [Laparoscopic surgery of gastric cancer]. An Sist Sanit Navar; 2005;28 Suppl 3:21-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic surgery of gastric cancer].
  • INTRODUCTION: The present state of minimally invasive surgery in gastric cancer is reviewed and its technical aspects are detailed.
  • In this study involving 101 patients with gastric adenocarcinoma, the mini-invasive laparoscopic approach was employed as a surgical tool with the "aim of treatment by laparoscopy".
  • CONCLUSIONS: Laparoscopic gastrectomy associated with any type of lymphadenectomy is a significant but safe intervention, with acceptable rates of morbidity and mortality in patients with advanced gastric cancer, who frequently present a bad general status.
  • [MeSH-major] Adenocarcinoma / surgery. Gastrectomy / methods. Laparoscopy. Stomach Neoplasms / surgery. Video-Assisted Surgery
  • [MeSH-minor] Actuarial Analysis. Adult. Aged. Aged, 80 and over. Data Interpretation, Statistical. Female. Follow-Up Studies. Humans. Laparotomy. Lymph Node Excision. Male. Middle Aged. Neoplasm Staging. Palliative Care. Prospective Studies. Stomach / pathology. Survival Analysis. Time Factors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16511576.001).
  • [ISSN] 1137-6627
  • [Journal-full-title] Anales del sistema sanitario de Navarra
  • [ISO-abbreviation] An Sist Sanit Navar
  • [Language] spa
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Spain
  •  go-up   go-down


17. Yu JC, Zhou H, Bai J, Yu Y, Geng JS, Qi JP, Fu SB: Human gastric adenocarcinoma allelotype on chromosomes 17 and 18. J Int Med Res; 2008 Mar-Apr;36(2):279-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human gastric adenocarcinoma allelotype on chromosomes 17 and 18.
  • Allelic losses of multiple chromosome loci in gastric adenocarcinoma suggest that inactivation of tumour suppressor genes in these regions may be important for tumourigenesis.
  • To define deletion intervals and find candidate tumour suppressor genes involved in gastric adenocarcinoma pathogenesis, a genome-wide search for loss of heterozygosity (LOH) was conducted in 45 patients with primary gastric adenocarcinoma.
  • LOH mapping showed allelic losses were widespread on both chromosomes and suggests the possibility that multiple tumour suppressor genes, including one or more that are unknown, might be inactivated in the aetiology of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Alleles. Chromosomes, Human, Pair 17 / genetics. Chromosomes, Human, Pair 18 / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18380938.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


18. Johnson AH, Frierson HF, Zaika A, Powell SM, Roche J, Crowe S, Moskaluk CA, El-Rifai W: Expression of tight-junction protein claudin-7 is an early event in gastric tumorigenesis. Am J Pathol; 2005 Aug;167(2):577-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of tight-junction protein claudin-7 is an early event in gastric tumorigenesis.
  • Trefoil factor-1 (Tff1) expression is remarkably down-regulated in nearly all human gastric cancers.
  • Therefore, we used the Tff1 knockout mouse model to detect molecular changes in preneoplastic gastric dysplasia.
  • Oligonucleotide microarray gene expression analysis of gastric dysplasia of Tff1-/- mice was compared to that of normal gastric mucosa of wild-type mice.
  • Quantitative real-time reverse transcriptase-polymerase chain reaction and immunohistochemistry showed that Cldn7 was overexpressed in all 10 Tff1-/- gastric dysplasia samples.
  • Comparison with our serial analysis of gene expression database of human gastric cancer revealed similar deregulation in human gastric cancers.
  • Quantitative real-time reverse transcriptase-polymerase chain reaction of human gastric adenocarcinoma samples indicated that, of these three genes, CLDN7 was the most frequently up-regulated gene.
  • Using immunohistochemistry, both mouse and human gastric glands overexpressed Cldn7 in dysplastic but not surrounding normal glands.
  • Cldn7 expression was observed in 30% of metaplasia, 80% of dysplasia, and 70% of gastric adenocarcinomas.
  • Interestingly, 82% of human intestinal-type gastric adenocarcinomas expressed Cldn7 whereas diffuse-type gastric adenocarcinomas did not (P < 0.001).
  • These results suggest that Cldn7 expression is an early event in gastric tumorigenesis that is maintained throughout tumor progression.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Pharmacol. 2000 Oct 15;60(8):1091-9 [11007946.001]
  • [Cites] J Pathol. 1999 Jul;188(3):312-7 [10419601.001]
  • [Cites] Ann N Y Acad Sci. 2000;915:129-35 [11193568.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Apr;2(4):285-93 [11283726.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):592-8 [11522743.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):6996-7001 [11585723.001]
  • [Cites] Genome Res. 2001 Oct;11(10):1686-98 [11591645.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):153-6 [11668491.001]
  • [Cites] Oncol Res. 2001;12(11-12):469-76 [11939410.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2625-9 [11980659.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1745-54 [12000726.001]
  • [Cites] J Cell Biol. 2002 May 27;157(5):761-70 [12034770.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):4061-4 [12124342.001]
  • [Cites] Int J Oncol. 2002 Sep;21(3):655-9 [12168114.001]
  • [Cites] Lab Invest. 2002 Oct;82(10):1319-26 [12379766.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6823-6 [12460893.001]
  • [Cites] J Cell Sci. 2003 Apr 1;116(Pt 7):1187-97 [12615962.001]
  • [Cites] Gastric Cancer. 2002;5 Suppl 1:5-11 [12772880.001]
  • [Cites] Int J Mol Med. 2003 Jul;12(1):3-9 [12792801.001]
  • [Cites] Nat Cell Biol. 2003 Jul;5(7):595-7 [12833061.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2567-75 [12855632.001]
  • [Cites] Lancet. 2003 Jul 26;362(9380):305-15 [12892963.001]
  • [Cites] J Membr Biol. 2003 Aug 1;194(3):187-97 [14502431.001]
  • [Cites] Med Electron Microsc. 2003 Sep;36(3):147-56 [14505058.001]
  • [Cites] Cancer. 2003 Nov 15;98(10):2184-91 [14601088.001]
  • [Cites] Sci STKE. 2004 Jan 20;2004(216):pe2 [14734784.001]
  • [Cites] Am J Pathol. 2004 Mar;164(3):903-14 [14982844.001]
  • [Cites] Am J Clin Pathol. 2004 Feb;121(2):226-30 [14983936.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3291-300 [15161682.001]
  • [Cites] Science. 1995 Oct 20;270(5235):484-7 [7570003.001]
  • [Cites] Science. 1996 Oct 11;274(5285):259-62 [8824193.001]
  • [Cites] Bioinformatics. 2000 Jul;16(7):650-1 [11038335.001]
  • (PMID = 16049341.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA093999; United States / NCI NIH HHS / CA / CA93999
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CLDN7 protein, human; 0 / Claudins; 0 / DNA-Binding Proteins; 0 / EGR1 protein, human; 0 / Early Growth Response Protein 1; 0 / Estrogens; 0 / Growth Inhibitors; 0 / Immediate-Early Proteins; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / Receptors, Cell Surface; 0 / TFF1 protein, human; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / epithelial membrane protein-1
  • [Other-IDs] NLM/ PMC1603560
  •  go-up   go-down


19. Costantini R, De Nicola P, Bianco F, Cotroneo AR, Iezzi R, Di Bartolomeo N, Innocenti P: Tumor vs non-tumor origin of occult and obscure gastrointestinal bleeding requiring hospitalization. Tumori; 2007 Sep-Oct;93(5):461-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Thirty-five cases of obscure and 27 cases of occult bleeding were examined; all received a definite diagnosis during hospitalization.
  • In the cases with obscure bleeding the diagnosis was inflammatory bowel disease (n = 7), angiodysplasia (5 gastric, 2 duodenal, 2 jejunal, 3 ileal, 4 right colon), small bowel tumors (4 non-Hodgkin lymphomas, 1 leiomyoma, 6 adenocarcinomas), and gastric metaplasia of Meckel's diverticulum (n = 1).
  • Intestinal resections were performed for all small bowel tumors (8 laparotomic, 3 laparoscopic), 5 angiodysplasias, all cases of inflammatory bowel disease and gastric metaplasia of Meckel's diverticulum; arterial embolization was performed for 11 angiodysplasias.
  • In the cases with occult bleeding the diagnosis was sigmoid colon polyps in 6 (treatment, endoscopic polypectomy) and right colon cancer in 21 (treatment, right hemicolectomy).
  • Thanks to modern technology, however, their diagnosis and treatment can nowadays be promptly and successfully achieved.
  • [MeSH-major] Gastrointestinal Hemorrhage / diagnosis. Intestinal Neoplasms / diagnosis. Occult Blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Capsules. Diagnosis, Differential. Endoscopy, Gastrointestinal. Female. Follow-Up Studies. Humans. Intestine, Small / pathology. Male. Middle Aged. Treatment Outcome. Videotape Recording

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18038878.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Capsules
  •  go-up   go-down


20. Molina Infante J, Hernández Alonso M, Martín Noguerol E, Pérez Gallardo B, Dueñas Sadornil C: [Alopecia areata as the initial paraneoplastic presentation of gastric adenocarcinoma]. Gastroenterol Hepatol; 2009 Feb;32(2):128-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Alopecia areata as the initial paraneoplastic presentation of gastric adenocarcinoma].
  • [Transliterated title] Alopecia areata como presentación inicial paraneoplásica de un adenocarcinoma gástrico.
  • [MeSH-major] Adenocarcinoma / complications. Alopecia Areata / etiology. Paraneoplastic Syndromes / etiology. Stomach Neoplasms / complications

  • Genetic Alliance. consumer health - Alopecia Areata.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19231692.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  •  go-up   go-down


21. Rocha FT, Lourenço LG, Jucá MJ, Costa V, Leal AT: Chemoprevention by celecoxib in reflux-induced gastric adenocarcinoma in Wistar rats that underwent gastrojejunostomy. Acta Cir Bras; 2009 May-Jun;24(3):189-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoprevention by celecoxib in reflux-induced gastric adenocarcinoma in Wistar rats that underwent gastrojejunostomy.
  • PURPOSE: To evaluate chemoprevention by celecoxib in cases of reflux-induced gastric adenocarcinoma, in Wistar rats that underwent gastrojejunostomy.
  • Changes in the mucosa of the gastric body of group 1 and in the gastrojejunal anastomosis of groups 2 and 3, observed in histopathological and immunohistochemical examinations, were compared.
  • RESULTS: Comparison between groups 2 and 3 relative to the presence of adenocarcinoma showed a statistically significant difference (p=0.0023).
  • CONCLUSION: Celecoxib had an inhibiting effect on gastric carcinogenesis induced by enterogastric reflux in an animal model.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CELECOXIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19504000.001).
  • [ISSN] 1678-2674
  • [Journal-full-title] Acta cirurgica brasileira
  • [ISO-abbreviation] Acta Cir Bras
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Pyrazoles; 0 / Sulfonamides; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


22. Hur H, Kim JY, Cho YK, Han SU: Technical feasibility of robot-sewn anastomosis in robotic surgery for gastric cancer. J Laparoendosc Adv Surg Tech A; 2010 Oct;20(8):693-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Technical feasibility of robot-sewn anastomosis in robotic surgery for gastric cancer.
  • BACKGROUND: Although several studies have reported on the feasibility of robot-assisted gastric cancer surgery using the da Vinci surgical system, reconstruction techniques have depended on staplers or hand sewing through minilaparotomy.
  • AIM: The aim of this study is to report on the feasibility of reconstruction methods using a robot-sewing technique in robotic surgery for treatment of gastric cancer.
  • PATIENT AND METHODS: Between January and April 2010, 7 patients in whom gastric adenocarcinoma was diagnosed underwent robotic surgery including robot-sewn anastomosis.
  • One patient was readmitted for stasis in the remnant stomach but conservatively recovered.
  • CONCLUSIONS: A robot-sewn anastomosis for reconstruction in robotic surgery for gastric cancer was feasible regardless of the reconstruction method.
  • [MeSH-major] Adenocarcinoma / surgery. Anastomosis, Surgical / methods. Robotics. Stomach Neoplasms / surgery. Suture Techniques

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20809816.001).
  • [ISSN] 1557-9034
  • [Journal-full-title] Journal of laparoendoscopic & advanced surgical techniques. Part A
  • [ISO-abbreviation] J Laparoendosc Adv Surg Tech A
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Moschetta M, Stabile Ianora AA, Anglani A, Marzullo A, Scardapane A, Angelelli G: Preoperative T staging of gastric carcinoma obtained by MDCT vessel probe reconstructions and correlations with histological findings. Eur Radiol; 2010 Jan;20(1):138-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative T staging of gastric carcinoma obtained by MDCT vessel probe reconstructions and correlations with histological findings.
  • This study aims to evaluate the diagnostic accuracy of 16-row multidetector CT (MDCT) and vessel probe reconstructions in the T staging of gastric carcinoma.
  • Fifty-three patients (39 men, 14 women, mean age 57.5) with an endoscopic diagnosis of gastric adenocarcinoma underwent CT examination.
  • A hypotonic drug was administered, and the gastric walls were distended by the ingestion of 400-600 ml of water.
  • MDCT is an accurate technique for the preoperative staging of gastric cancer.
  • [MeSH-major] Stomach Neoplasms / diagnostic imaging. Stomach Neoplasms / pathology. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiat Med. 2000 Jan-Feb;18(1):47-54 [10852655.001]
  • [Cites] J Comput Assist Tomogr. 1997 Jan-Feb;21(1):73-81 [9022773.001]
  • [Cites] J Comput Assist Tomogr. 2007 Jan-Feb;31(1):98-103 [17259840.001]
  • [Cites] Radiol Med. 2001 Jul-Aug;102(1-2):32-6 [11677435.001]
  • [Cites] Abdom Imaging. 2006 Sep-Oct;31(5):514-20 [16465577.001]
  • [Cites] Radiol Med. 2003 Nov-Dec;106(5-6):467-80 [14735012.001]
  • [Cites] Clin Imaging. 2001 May-Jun;25(3):181-6 [11679225.001]
  • [Cites] AJR Am J Roentgenol. 2005 Nov;185(5):1152-8 [16247125.001]
  • [Cites] AJR Am J Roentgenol. 2000 Jun;174(6):1551-7 [10845479.001]
  • [Cites] Eur Radiol. 2000;10 (12 ):1877-85 [11305564.001]
  • [Cites] J Surg Oncol. 2009 Jan 1;99(1):20-7 [18937292.001]
  • [Cites] Radiology. 2007 Feb;242(2):472-82 [17255419.001]
  • [Cites] Gastrointest Endosc. 2004 May;59(6):619-26 [15114303.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):2107-16 [17513817.001]
  • [Cites] Radiology. 1992 Oct;185(1):173-8 [1523303.001]
  • [Cites] AJR Am J Roentgenol. 2007 Aug;189(2):299-305 [17646454.001]
  • [Cites] J Comput Assist Tomogr. 2000 Sep-Oct;24(5):777-82 [11045702.001]
  • [Cites] Radiol Med. 1997 Nov;94(5):486-91 [9465214.001]
  • [Cites] Rev Esp Enferm Dig. 2006 Aug;98(8):582-90 [17048994.001]
  • [Cites] Abdom Imaging. 2005 Jul-Aug;30(4):465-72 [15785907.001]
  • [Cites] Eur Radiol. 1996;6(3):358-61 [8798006.001]
  • [Cites] World J Gastroenterol. 2006 Jan 7;12 (1):43-7 [16440415.001]
  • [Cites] Surgery. 1993 Jan;113(1):14-27 [8417483.001]
  • [Cites] Abdom Imaging. 2002 Jul-Aug;27(4):376-83 [12066235.001]
  • [Cites] J Comput Assist Tomogr. 1998 Mar-Apr;22(2):288-94 [9530396.001]
  • [Cites] Radiology. 2005 Dec;237(3):961-6 [16251394.001]
  • [Cites] Eur J Radiol. 2002 Jun;42(3):181-92 [12044697.001]
  • [Cites] World J Gastroenterol. 2005 Aug 7;11(29):4592-5 [16052695.001]
  • [Cites] Abdom Imaging. 2009 Jan-Feb;34(1):26-34 [18311495.001]
  • [Cites] Radiology. 2004 Feb;230(2):465-71 [14752188.001]
  • [Cites] Radiology. 2005 Sep;236(3):879-85 [16020558.001]
  • [Cites] Gastric Cancer. 2005;8(1):29-34 [15747171.001]
  • (PMID = 19504100.001).
  • [ISSN] 1432-1084
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


24. Shiozaki A, Miyazaki H, Niisato N, Nakahari T, Iwasaki Y, Itoi H, Ueda Y, Yamagishi H, Marunaka Y: Furosemide, a blocker of Na+/K+/2Cl- cotransporter, diminishes proliferation of poorly differentiated human gastric cancer cells by affecting G0/G1 state. J Physiol Sci; 2006 Dec;56(6):401-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Furosemide, a blocker of Na+/K+/2Cl- cotransporter, diminishes proliferation of poorly differentiated human gastric cancer cells by affecting G0/G1 state.
  • The aim of the present study was to investigate whether an NKCC blocker affects cancer cell growth.
  • We found that poorly differentiated gastric adenocarcinoma cells (MKN45) expressed the mRNA of NKCC1 three times higher than moderately differentiated ones (MKN28) and that the NKCC in MKN45 showed higher activity than that in MKN28.
  • Using flow cytometrical analysis, we found that the exposure to furosemide brought MKN45 cells to spend more time at the G(0)/G(1) phase, but not MKN28 cells.
  • Based on these observations, we indicate that furosemide diminishes cell growth by delaying the G(1)-S phase progression in poorly differentiated gastric adenocarcinoma cells, which show high expression and activity of NKCC, but not in moderately differentiated gastric adenocarcinoma cells with low expression and NKCC activity.
  • [MeSH-major] Adenocarcinoma / pathology. Cell Proliferation / drug effects. Furosemide / pharmacology. Sodium Potassium Chloride Symporter Inhibitors / pharmacology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827858893 for PMID:17052386 [PharmGKB] .
  • Hazardous Substances Data Bank. FUROSEMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17052386.001).
  • [ISSN] 1880-6546
  • [Journal-full-title] The journal of physiological sciences : JPS
  • [ISO-abbreviation] J Physiol Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Sodium Potassium Chloride Symporter Inhibitors; 0 / Sodium-Potassium-Chloride Symporters; 7LXU5N7ZO5 / Furosemide
  •  go-up   go-down


25. Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH, Greskovich JF, Anne PR, Bradley JD, Willett C, Rich TA: Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol; 2006 Aug 20;24(24):3953-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response.
  • PURPOSE: Preoperative therapy for localized gastric cancer has considerable appeal.
  • PATIENTS AND METHODS: Patients with localized gastric adenocarcinoma were eligible.
  • CONCLUSION: For localized gastric cancer, preoperative chemoradiotherapy strategy achieved a pathCR rate of more than 20% in a cooperative group setting.
  • With some refinements, this preoperative chemoradiotherapy strategy is poised for a randomized comparison with postoperative adjuvant chemoradiotherapy in patients with gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy. Neoadjuvant Therapy. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16921048.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA21661; United States / NCI NIH HHS / CA / U10 CA32115; United States / NCI NIH HHS / CA / U10 CA37422
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


26. Di Bartolomeo M, Buzzoni R, Mariani L, Ferrario E, Katia D, Gevorgyan A, Zilembo N, Bordonaro R, Bochicchio AM, Massidda B, Ardizzoia A, Marini G, Aitini E, Schieppati G, Comella G, Pinotti G, Palazzo S, Cicero G, Bajetta E, Italian Trial in Medical Oncology (ITMO) Group, Villa E, Fagnani D, Reguzzoni G, Agostana B, Oliani C, Kildani B, Duro M, Botta M, Mozzana R, Mantovani G: Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial. Oncology; 2006;71(5-6):341-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial.
  • OBJECTIVE: Combination therapies of fluorouracil (FU) with irinotecan (CPT-11) and docetaxel plus cisplatin have been proven to be active in metastatic gastric cancer.
  • METHODS: 169 patients with radically resected gastric cancer were randomized to receive CPT-11 (180 mg/m2 day 1), leucovorin (100 mg/m2 days 1-2), FU (400-600 mg/m2 days 1-2, q 14; for four cycles; FOLFIRI regimen), followed by docetaxel (85 mg/m2 day 1), cisplatin (75 mg/m2 day 1, q 21; for three cycles; arm A), or MMC (8 mg/m2 days 1-2 as 2-hour infusion, q 42; for four cycles; arm B).
  • All patients had histologically confirmed gastric carcinoma with nodal positivity or pT3/4.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery. Taxoids / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • [ErratumIn] Oncology. 2007;73(5-6):406. Ardizzoni, Antonio [corrected to Ardizzoia, Antonio]
  • (PMID = 17855795.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; IFL protocol
  •  go-up   go-down


27. Trejo-de la O A, Torres J, Pérez-Rodríguez M, Camorlinga-Ponce M, Luna LF, Abdo-Francis JM, Lazcano E, Maldonado-Bernal C: TLR4 single-nucleotide polymorphisms alter mucosal cytokine and chemokine patterns in Mexican patients with Helicobacter pylori-associated gastroduodenal diseases. Clin Immunol; 2008 Nov;129(2):333-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Helicobacter pylori is associated with peptic ulcer and gastric adenocarcinoma.
  • We aimed to evaluate the association of TLR2/R753Q and TLR4/D299G/T399I SNPs with gastroduodenal diseases; and study the effect of SNPs on cytokine and chemokine expression in the gastric mucosa.
  • TLR4/D299G/T399I polymorphisms were more frequent in duodenal ulcer and showed a trend in gastric cancer, when compared with non-atrophic gastritis.
  • SNPs in TLR4 gene had an association with severe H. pylori-associated disease and with modified pattern of inflammatory cytokines and chemokines in the gastric mucosa.
  • [MeSH-major] Chemokines / analysis. Cytokines / analysis. Duodenal Ulcer / genetics. Gastritis / genetics. Helicobacter Infections / complications. Helicobacter pylori. Polymorphism, Single Nucleotide. Stomach Neoplasms / genetics. Toll-Like Receptor 2 / genetics. Toll-Like Receptor 4 / genetics

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18755634.001).
  • [ISSN] 1521-7035
  • [Journal-full-title] Clinical immunology (Orlando, Fla.)
  • [ISO-abbreviation] Clin. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chemokines; 0 / Cytokines; 0 / TLR2 protein, human; 0 / TLR4 protein, human; 0 / Toll-Like Receptor 2; 0 / Toll-Like Receptor 4
  •  go-up   go-down


28. Lee SW, Kang SB, Kim YS, Nam SW, Lee DS, Lee HK, Han SW: [Expression of c-erbB-2 and c-met proteins in gastric adenoma and adenocarcinoma]. Korean J Gastroenterol; 2007 Mar;49(3):152-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of c-erbB-2 and c-met proteins in gastric adenoma and adenocarcinoma].
  • BACKGROUND/AIMS: The aim of this study was to investigate the immunohistochemical overexpression of c-erbB-2 and c-met proteins according to the histopathological parameters such as grade of dysplasia, histological type, depth of invasion, lymph node metastasis, and TNM stage in gastric adenoma and gastric adenocarcinoma.
  • METHODS: Immunohistochemical staining using monoclonal c-erbB-2 and c-met antibodies was performed on paraffin embedded specimens in 43 adenomas and 44 adenocarcinomas.
  • RESULTS: The expression rate of c-erbB-2 was higher in adenomas (91%) than adenocarcinomas (30%).
  • The expression rate of c-met was higher in adenocarcinomas (77%) than adenomas (49%).
  • In adenocarcinoma, c-met expression was significantly related with lymph node metastasis.
  • CONCLUSIONS: c-erbB-2 would be involved in the development of relatively early stage gastric carcinogenesis. c-erbB-2 is related with histologic type and c-met with lymph node metastasis in gastric carcinomas.
  • Although meaning for the expression of these proteins in gastric carcinomas would be different, these proteins may play as important oncogenes in gastric carcinogenesis.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Proto-Oncogene Proteins c-met / metabolism. Receptor, ErbB-2 / metabolism. Stomach Neoplasms / metabolism


29. Ishiura Y, Yamamoto H, Terasaki Y, Ishida Y, Yokawa S, Fukushima W, Hirosawa H, Izumi R, Kodama K, Motoi I, Tanikawa F, Ichihashi K, Maruyama K, Miyazu M, Yoneda K, Saito K, Kasahara K, Fujimura M: [A case of synchronous triple cancer involving lung, stomach and bladder, responding to combination chemotherapy of S-1 and cisplatin]. Gan To Kagaku Ryoho; 2008 Aug;35(8):1395-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of synchronous triple cancer involving lung, stomach and bladder, responding to combination chemotherapy of S-1 and cisplatin].
  • Succeeding upper gastro-intestinal fiberscopy and cystoscopy revealed poorly-differentiated adenocarcinoma of the stomach and urothelial carcinoma of the bladder.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Lung Neoplasms / drug therapy. Neoplasms, Multiple Primary / drug therapy. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use. Urinary Bladder Neoplasms / drug therapy


30. Perrone M, Muñoz L, Camorlinga M, Correnti M, Cavazza ME, Lecuna V, Torres J: [Importance of IgG anti-CagA antibodies of Helicobacter pylori in Venezuelan patients with gastric diseases]. Invest Clin; 2005 Dec;46(4):357-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Importance of IgG anti-CagA antibodies of Helicobacter pylori in Venezuelan patients with gastric diseases].
  • [Transliterated title] Importancia de la respuesta humoral de IgG anti-CagA de Helicobacter pylori en pacientes venezolanos con enfermedades de las vías digestivas superiores.
  • It is associated with chronic gastritis, peptic ulcer disease and constitutes a major risk factor for gastric adenocarcinoma and lymphoma.
  • We evaluated 66 patients from the Hospital Universitario de Caracas, attending in the gastroscopy service. H. pylori infection was detected by culture and rapid urease test.
  • The positive rates of CagA antibodies in patients with gastric ulcer, gastric cancer and chronic gastritis were 87.8%, 77.7% y 40.8% respectively.
  • The serum antibodies anti-CagA were similar between peptic ulcer disease and gastric cancer patients.
  • [MeSH-major] Antigens, Bacterial / immunology. Bacterial Proteins / immunology. Immunoglobulin G / immunology. Stomach Diseases / immunology. Stomach Diseases / microbiology

  • MedlinePlus Health Information. consumer health - Stomach Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16353543.001).
  • [ISSN] 0535-5133
  • [Journal-full-title] Investigación clínica
  • [ISO-abbreviation] Invest Clin
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Venezuela
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / Bacterial Proteins; 0 / Immunoglobulin G; 0 / cagA protein, Helicobacter pylori; EC 3.5.1.5 / Urease
  •  go-up   go-down


31. Moenig SP, Luebke T, Baldus SE, Schroeder W, Bollschweiler E, Schneider PM, Hoelscher AH: Feasibility of sentinel node concept in gastric carcinoma: clinicopathological analysis of gastric cancer with solitary lymph node metastases. Anticancer Res; 2005 Mar-Apr;25(2B):1349-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of sentinel node concept in gastric carcinoma: clinicopathological analysis of gastric cancer with solitary lymph node metastases.
  • BACKGROUND: The feasibility and diagnostic reliability of sentinel lymph node biopsy of gastric carcinoma are still unclear and controversial.
  • PATIENTS AND METHODS: To assess the applicability of the sentinel node concept to gastric carcinoma, we retrospectively analyzed the location of metastatic lymph nodes in patients with only one or two lymph node metastases.
  • RESULTS: A total of 135 patients, who underwent gastrectomy with D2 lymphadenectomy for primary gastric adenocarcinoma between 1997 and 2001, were enrolled in this study.
  • Skip metastases were only seen in one patient with cardia carcinoma and lymph node involvement of compartment II (left gastric artery).
  • CONCLUSION: In patients with gastric carcinoma, especially in early stage carcinoma, the phenomenon of skip metastasis is infrequent.
  • Therefore, the sentinel node concept may be feasible in gastric cancer.
  • [MeSH-major] Sentinel Lymph Node Biopsy. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15865090.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


32. Wu WK, Shin VY, Ye YN, Wong HP, Huang FY, Hui MK, Lam EK, Cho CH: Heparin increases human gastric carcinoma cell growth. Anticancer Res; 2006 Jan-Feb;26(1A):439-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heparin increases human gastric carcinoma cell growth.
  • BACKGROUND: Heparin has been widely used to prevent cancer-associated thromboembolism in cancer patients.
  • Recent evidence reveals that heparin could modulate cell proliferation in the stomach.
  • The effect of heparin on gastric cancer growth, however, is unknown.
  • The effect of heparin on the proliferation of a human gastric adenocarcinoma cell line, BGC-823, was investigated.
  • RESULTS: Heparin significantly increased cell proliferation in BGC-823 cancer cells by 15.5% at the dose of 0.2 microg/ml.
  • CONCLUSION: Our results suggest that heparin can promote the proliferation and up-regulation of c-Myc protein expression in gastric cancer cells.
  • [MeSH-major] Heparin / pharmacology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HEPARIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16475731.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / RNA, Messenger; 9005-49-6 / Heparin; EC 1.14.99.1 / Cyclooxygenase 2; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


33. Ma X, Chen K, Huang S, Zhang X, Adegboyega PA, Evers BM, Zhang H, Xie J: Frequent activation of the hedgehog pathway in advanced gastric adenocarcinomas. Carcinogenesis; 2005 Oct;26(10):1698-705
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent activation of the hedgehog pathway in advanced gastric adenocarcinomas.
  • Recent studies indicate that the hedgehog pathway activation occurs in the stomach and other gastrointestinal cancers.
  • Here, we report our findings that the elevated expression of hedgehog target genes human patched gene 1 (PTCH1) or Gli1 occurs in 63 of the 99 primary gastric cancers.
  • The sonic hedgehog (Shh) transcript is localized to the cancer tissue, whereas expression of Gli1 and PTCH1 is observed both in the cancer and in the surrounding stroma.
  • Treatment of gastric cancer cells with KAAD-cyclopamine, a hedgehog signaling inhibitor, decreases expression of Gli1 and PTCH1, resulting in cell growth inhibition and apoptosis.
  • Thus, our analysis of in vivo tissues indicates that the hedgehog pathway is frequently activated in advanced gastric adenocarcinomas; our in vitro studies suggest that hedgehog signaling contributes to gastric cancer cell growth.
  • These data predict that targeted inhibition of the hedgehog pathway may be effective in the prevention and treatment of advanced gastric adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Stomach Neoplasms / pathology. Trans-Activators / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15905200.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA94160
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gli protein; 0 / Hedgehog Proteins; 0 / Oncogene Proteins; 0 / Receptors, Cell Surface; 0 / SHH protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / patched receptors
  •  go-up   go-down


34. Pinto RP, Lima FK, Kulkzynski JM, Moreira LF: Expression of P16 and PDGFR-beta in gastric adenocarcinoma. Rev Col Bras Cir; 2009 Jul;36(3):199-203
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of P16 and PDGFR-beta in gastric adenocarcinoma.
  • OBJECTIVES: To detect immunohistochemistry expression of p16 and PDGFR-beta on gastric adenocarcinoma.
  • METHODS: Thirty six patients submitted to surgery for gastric adenocarcinoma between 1998 and 2002 at Santa Casa de Porto Alegre Hospital have been studied.
  • [MeSH-major] Adenocarcinoma / metabolism. Neoplasm Proteins / biosynthesis. Receptor, Platelet-Derived Growth Factor beta / biosynthesis. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20076898.001).
  • [ISSN] 1809-4546
  • [Journal-full-title] Revista do Colégio Brasileiro de Cirurgiões
  • [ISO-abbreviation] Rev Col Bras Cir
  • [Language] eng; por
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / P16 protein, human; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  •  go-up   go-down


35. Huang Y, Zhu Z, Sun M, Wang J, Guo R, Shen L, Wu W: Critical role of aquaporin-3 in the human epidermal growth factor-induced migration and proliferation in the human gastric adenocarcinoma cells. Cancer Biol Ther; 2010 Jun 15;9(12):1000-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Critical role of aquaporin-3 in the human epidermal growth factor-induced migration and proliferation in the human gastric adenocarcinoma cells.
  • AIMS: The aim of this study was to investigate whether AQP3 expression in the human gastric carcinoma cell lines, AGS and SGC7901, enhances cell migration and proliferation.
  • RESULTS: Here, we showed that AQP3 is expressed in the human gastric cancer cell lines, AGS and SGC7901.
  • The hEGF induced AQP3 expression in a time- and dose-dependent manner and increased gastric cancer cell migration and proliferation.
  • CONCLUSIONS: Collectively, our findings provide for the first time that AQP3 plays a critical role in hEGF-induced cancer cell migration and proliferation and that hEGF induces AQP3 expression via ERK signal transduction pathways.
  • These finds provide evidence for a novel role of AQP3 in human gastric carcinoma as a potentially important determinant of tumor growth and spread.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Aquaporin 3 / metabolism. Epidermal Growth Factor / physiology. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20364107.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 158801-98-0 / Aquaporin 3; 62229-50-9 / Epidermal Growth Factor
  •  go-up   go-down


36. Kaźmierczak M, Lewandowski K, Wojtukiewicz MZ, Turowiecka Z, Kołacz E, Lojko A, Skrzydlewska E, Zawilska K, Komarnicki M: Cancer procoagulant in patients with adenocarcinomas. Blood Coagul Fibrinolysis; 2005 Nov;16(8):543-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer procoagulant in patients with adenocarcinomas.
  • Cancer procoagulant (CP) is a cysteine proteinase that may be produced by malignant and foetal tissue.
  • The possible role of CP in the pathogenesis of cancer-related thrombosis has been suggested recently.
  • The purpose of the study was to evaluate coagulation prothrombotic markers and their relation to CP concentration in the blood of patients with gastrointestinal adenocarcinomas (GIAC).
  • The study group consisted of 45 patients with confirmed diagnosis of adenocarcinoma (stomach, 18 patients; colon, 27 patients) and without evident metastatic disease.
  • [MeSH-major] Adenocarcinoma / blood. Colonic Neoplasms / blood. Cysteine Endopeptidases / blood. Neoplasm Proteins / blood. Stomach Neoplasms / blood. Venous Thrombosis / blood

  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16269926.001).
  • [ISSN] 0957-5235
  • [Journal-full-title] Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  • [ISO-abbreviation] Blood Coagul. Fibrinolysis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Blood Proteins; 0 / Neoplasm Proteins; EC 3.4.22.- / Cysteine Endopeptidases; EC 3.4.22.26 / cancer procoagulant
  •  go-up   go-down


37. Kim YG, Jang BI, Kim TN: A matched case-control study of a novel Acid-pump antagonist and proton-pump inhibitor for the treatment of iatrogenic ulcers caused by endoscopic submucosal dissection. Gut Liver; 2010 Mar;4(1):25-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We reviewed the medical records of patients who underwent endoscopic submucosal dissection (ESD) for gastric neoplasia at Yeungnam University Hospital between January 2008 and May 2009.
  • In the revaprazan group, only one patient had stage H2 disease: a 54-year-old man with a 5.5-cm lesion after ESD of the ulcer, type IIa early gastric cancer, and adenocarcinoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 1992 May;33(5):617-21 [1319381.001]
  • [Cites] J Pharmacol Exp Ther. 2008 Jul;326(1):163-70 [18411413.001]
  • [Cites] Gastroenterology. 1992 Aug;103(2):407-13 [1634059.001]
  • [Cites] Gastroenterology. 1992 Feb;102(2):695-8 [1732139.001]
  • [Cites] Dig Dis Sci. 1988 May;33(5):619-24 [3282850.001]
  • [Cites] Biochem Pharmacol. 1995 Nov 9;50(10):1543-9 [7503755.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1995;35:277-305 [7598495.001]
  • [Cites] Dig Dis Sci. 1996 Oct;41(10):2039-47 [8888719.001]
  • [Cites] Free Radic Biol Med. 1996;21(5):727-31 [8891677.001]
  • [Cites] Pharmacotherapy. 1997 Jan-Feb;17(1):22-37 [9017763.001]
  • [Cites] J Clin Biochem Nutr. 2008 May;42(3):191-6 [18545640.001]
  • [Cites] Dig Dis Sci. 2009 Jul;54(7):1494-9 [19005762.001]
  • [Cites] Am J Gastroenterol. 2009 May;104(5):1130-4 [19337238.001]
  • [Cites] Aliment Pharmacol Ther. 2000 Apr;14 Suppl 1:74-81 [10807407.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Dec;281(6):G1502-11 [11705756.001]
  • [Cites] J Clin Pharmacol. 2004 Jan;44(1):73-82 [14681344.001]
  • [Cites] Wound Repair Regen. 2004 Jan-Feb;12(1):93-9 [14974970.001]
  • [Cites] Gastrointest Endosc. 2004 Aug;60(2):213-7 [15278047.001]
  • [Cites] Hum Mol Genet. 2004 Nov 15;13(22):2813-21 [15385447.001]
  • [Cites] Chin J Dig Dis. 2005;6(3):119-21 [16045601.001]
  • [Cites] J Gastroenterol. 2005 Jul;40(7):685-9 [16082584.001]
  • [Cites] J Biol Chem. 2006 Aug 18;281(33):23740-7 [16754665.001]
  • [Cites] J Med Invest. 2007 Feb;54(1-2):83-90 [17380018.001]
  • [Cites] Am J Physiol. 1992 Jun;262(6 Pt 2):H1955-8 [1320341.001]
  • (PMID = 20479909.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2871596
  • [Keywords] NOTNLM ; Acid pump antagonists / Endoscopic submucosal dissection / Proton pump inhibitors / Rabeprazole / Revaprazan
  •  go-up   go-down


38. Blanke CD, Chansky K, Christman KL, Hundahl SA, Issell BF, Van Veldhuizen PJ Jr, Budd GT, Abbruzzese JL, Macdonald JS: S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach. Am J Clin Oncol; 2010 Apr;33(2):117-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach.
  • OBJECTIVE: The primary objective of this trial was to evaluate the response rate for trimetrexate in conjunction with 5-FU and leucovorin (LV) (= TFL) in the treatment of advanced gastric cancer in a phase II, cooperative group setting.
  • METHODS: Patients with locally advanced, unresectable, or metastatic adenocarcinoma of the stomach received trimetrexate 110 mg/m IV over 60 minutes day 1, followed by 5-FU 500 mg/m IV bolus and LV 200 mg/m IV over 60 minutes day 2, followed by oral LV 15 mg every 6 hours x 7 doses, all weekly for 6 weeks followed by 2 weeks of rest, continued until progression.
  • Two patients died as a result of therapy, 1 because of infection without significant neutropenia, and 1 due to perforation of a responding gastric lesion.
  • CONCLUSIONS: This regimen achieves response rates comparable to other 5-FU-based regimens, when used in treatment of incurable gastric cancer.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. TRIMETREXATE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 2000 May;58(4):273-9 [10838491.001]
  • [Cites] Ann Oncol. 2008 Apr;19(4):729-33 [18083691.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):641-6 [11857295.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):87-91 [11863117.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):92-4 [11865815.001]
  • [Cites] Cancer Res. 1977 Jan;37(1):327-8 [830420.001]
  • [Cites] J Biol Chem. 1981 Feb 25;256(4):1695-704 [6161926.001]
  • [Cites] Cancer Res. 1982 May;42(5):1696-702 [6461409.001]
  • [Cites] Biochem Pharmacol. 1984 May 15;33(10):1697-9 [6233981.001]
  • [Cites] NCI Monogr. 1987;(5):105-9 [2963228.001]
  • [Cites] NCI Monogr. 1987;(5):99-104 [2963231.001]
  • [Cites] Cancer Res. 1988 Sep 1;48(17):5029-35 [2970294.001]
  • [Cites] J Natl Cancer Inst. 1989 Jan 18;81(2):124-30 [2909752.001]
  • [Cites] Eur J Cancer Clin Oncol. 1989 Jun;25(6):977-82 [2526736.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;24(5):314-20 [2758561.001]
  • [Cites] Cancer Res. 1989 Oct 15;49(20):5586-90 [2477146.001]
  • [Cites] Anticancer Res. 1989 Jul-Aug;9(4):1025-6 [2817784.001]
  • [Cites] Invest New Drugs. 1990 May;8(2):159-66 [2143500.001]
  • [Cites] J Natl Cancer Inst. 1992 Jul 1;84(13):1033-8 [1376779.001]
  • [Cites] Invest New Drugs. 1992 Nov;10(4):239-53 [1487397.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):37-41 [8508427.001]
  • [Cites] J Clin Oncol. 1994 Apr;12(4):695-700 [7512128.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):915-20 [9060528.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):269-72 [10390007.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4922-7 [17050876.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4991-7 [17075117.001]
  • [Cites] N Engl J Med. 2008 Jan 3;358(1):36-46 [18172173.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Clin Oncol. 2000 Dec 1;18(23):4001-3 [11099333.001]
  • (PMID = 19770625.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / N01 CA004919; United States / NCI NIH HHS / CA / U10 CA027057; United States / NCI NIH HHS / CA / N01 CA035176; United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / CA46136; United States / NCI NIH HHS / CA / U10 CA004919; United States / NCI NIH HHS / CA / N01 CA035431; United States / NCI NIH HHS / CA / CA22433; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / U10 CA045560; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / CA032102-32; United States / NCI NIH HHS / CA / U10 CA063845; United States / NCI NIH HHS / CA / N01 CA032102; United States / NCI NIH HHS / CA / U10 CA035192; United States / NCI NIH HHS / CA / CA58658; United States / NCI NIH HHS / CA / CA35996; United States / NCI NIH HHS / CA / CA63845; United States / NCI NIH HHS / CA / N01 CA035119; United States / NCI NIH HHS / CA / CA52757; United States / NCI NIH HHS / CA / CA45377; United States / NCI NIH HHS / CA / U10 CA032102-32; United States / NCI NIH HHS / CA / N01 CA063844; United States / NCI NIH HHS / CA / CA46282; United States / NCI NIH HHS / CA / U10 CA045461; United States / NCI NIH HHS / CA / U10 CA032102; United States / NCI NIH HHS / CA / CA35119; United States / NCI NIH HHS / CA / U10 CA046282; United States / NCI NIH HHS / CA / CA46368; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / N01 CA038926; United States / NCI NIH HHS / CA / CA45461; United States / NCI NIH HHS / CA / U10 CA067575; United States / NCI NIH HHS / CA / N01 CA027057; United States / NCI NIH HHS / CA / U10 CA045377; United States / NCI NIH HHS / CA / CA35192; United States / NCI NIH HHS / CA / U10 CA020319; United States / NCI NIH HHS / CA / CA46113; United States / NCI NIH HHS / CA / U10 CA038926; United States / NCI NIH HHS / CA / CA35176; United States / NCI NIH HHS / CA / CA58686; United States / NCI NIH HHS / CA / CA63844; United States / NCI NIH HHS / CA / U10 CA042777; United States / NCI NIH HHS / CA / CA27057; United States / NCI NIH HHS / CA / U10 CA035431; United States / NCI NIH HHS / CA / U10 CA035119; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / U10 CA046368; United States / NCI NIH HHS / CA / N01 CA067575; United States / NCI NIH HHS / CA / U10 CA052654; United States / NCI NIH HHS / CA / CA76429; United States / NCI NIH HHS / CA / CA04919; United States / NCI NIH HHS / CA / U10 CA035176; United States / NCI NIH HHS / CA / CA67575; United States / NCI NIH HHS / CA / U10 CA063844; United States / NCI NIH HHS / CA / N01 CA045560
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; UPN4ITI8T4 / Trimetrexate
  • [Other-IDs] NLM/ NIHMS244743; NLM/ PMC2967385
  •  go-up   go-down


39. Liu YJ, Yang Z, Hao LS, Xia L, Jia QB, Wu XT: Synchronous incidental gastrointestinal stromal and epithelial malignant tumors. World J Gastroenterol; 2009 Apr 28;15(16):2027-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From January 1, 2000 to December 31, 2007, 13804 cases of gastrointestinal epithelial malignant tumor (EMT) and 521 cases of pancreatic adenocarcinoma (PAC) were successfully treated with surgery at the Department of General Surgery and the Department of Thoracic Surgery, West China Hospital, Sichuan University, China.
  • Of these tumors, 27 were found in 1.13% patients with esophageal squamous cell carcinoma (ESCC), 22 in 0.53% patients with gastric adenocarcinoma (GAC), 2 in 0.38% patients with PAC, 2 in 0.03% patients with colorectal adenocarcinoma, and 1 in one patient with GAC accompanying ESCC, respectively.

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2000 May;124(5):682-6 [10782147.001]
  • [Cites] Am J Surg Pathol. 2007 Nov;31(11):1629-35 [18059218.001]
  • [Cites] Virchows Arch. 2001 Jan;438(1):1-12 [11213830.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 May;23(4):255-6 [11846308.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Sep;17(9):1033-6 [12167128.001]
  • [Cites] J Clin Gastroenterol. 2002 Oct;35(4):332-4 [12352297.001]
  • [Cites] J Gastroenterol. 2002;37(11):947-53 [12483251.001]
  • [Cites] J Exp Clin Cancer Res. 2002 Dec;21(4):617-20 [12636111.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1417-8 [12663737.001]
  • [Cites] Intern Med. 2004 Feb;43(2):102-5 [15005250.001]
  • [Cites] Med Sci Monit. 2004 Aug;10(8):LE13-4 [15278004.001]
  • [Cites] J Clin Pathol. 2004 Oct;57(10):1118-9 [15452175.001]
  • [Cites] Digestion. 1999 Jul-Aug;60(4):363-6 [10394032.001]
  • [Cites] Ann Diagn Pathol. 2005 Feb;9(1):49-53 [15692952.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):821-9 [15648083.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Jun;20(6):818-24 [15946127.001]
  • [Cites] Z Gastroenterol. 2005 Sep;43(9):1025-30 [16142610.001]
  • [Cites] Obes Surg. 2005 Nov-Dec;15(10):1384-8 [16354516.001]
  • [Cites] World J Gastroenterol. 2006 Feb 7;12(5):815-7 [16521203.001]
  • [Cites] Rev Esp Enferm Dig. 2006 May;98(5):387-9 [16944999.001]
  • [Cites] World J Gastroenterol. 2006 Sep 7;12(33):5360-2 [16981268.001]
  • [Cites] Arch Pathol Lab Med. 2006 Oct;130(10):1466-78 [17090188.001]
  • [Cites] Hum Pathol. 2006 Dec;37(12):1527-35 [16996566.001]
  • [Cites] Surg Today. 2007;37(1):74-7 [17186352.001]
  • [Cites] Gastroenterol Hepatol. 2007 Nov;30(9):534-7 [17980131.001]
  • [Cites] Ann Thorac Surg. 2000 Aug;70(2):660-2 [10969699.001]
  • (PMID = 19399938.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2675096
  •  go-up   go-down


40. Lee JH, Ryu KW, Lee JS, Lee JR, Kim CG, Choi IJ, Park SR, Kook MC, Kim YW, Bae JM: Decisions for extent of gastric surgery in gastric cancer patients: younger patients require more attention than the elderly. J Surg Oncol; 2007 May 1;95(6):485-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decisions for extent of gastric surgery in gastric cancer patients: younger patients require more attention than the elderly.
  • BACKGROUND AND OBJECTIVES: There is a prevailing belief that young patients with gastric adenocarcinomas have a more aggressive disease.
  • METHODS: We reviewed the prospectively collected database of 753 gastric adenocarcinomas patients who had undergone curative gastrectomy.
  • CONCLUSIONS: The present study showed that intra-operative under-staging was more common in young patients with gastric cancer, especially with stage I disease.
  • This finding raises the concern for inaccurate diagnosis and surgical under treatment in younger patients with stage I gastric cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Gastrectomy / methods. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • SciCrunch. The Antibody Registry: Reagent: Antibodies .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Wiley-Liss, Inc.
  • (PMID = 17195172.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Tajima Y, Yamazaki K, Makino R, Nishino N, Masuda Y, Aoki S, Kato M, Morohara K, Kusano M: Differences in the histological findings, phenotypic marker expressions and genetic alterations between adenocarcinoma of the gastric cardia and distal stomach. Br J Cancer; 2007 Feb 26;96(4):631-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in the histological findings, phenotypic marker expressions and genetic alterations between adenocarcinoma of the gastric cardia and distal stomach.
  • Adenocarcinoma of the gastric cardia (C-Ca) is possibly a specific subtype of gastric carcinoma.
  • The purpose of this study was to clarify the differences in the clinicopathological characteristics between C-Ca and adenocarcinoma of the distal stomach (D-Ca), and also the differences in the expressions of gastric and intestinal phenotypic markers and genetic alterations between the two.
  • The phenotypic marker expressions examined were those of human gastric mucin (HGM), MUC6, MUC2 and CD10.
  • Oesophageal invasion by the tumour beyond the oesophago-gastric junction (OGJ) was found in 56.9% of cases with C-Ca; LVI in the area of oesophageal invasion was demonstrated in 61% of these cases.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Biomarkers, Tumor / genetics. DNA, Neoplasm / genetics. Gene Expression Regulation, Neoplastic / genetics. Stomach Neoplasms / genetics. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 1994 Jun;129(6):609-14 [8204035.001]
  • [Cites] Gastroenterology. 1993 Feb;104(2):510-3 [8425693.001]
  • [Cites] Gastroenterology. 1995 Sep;109(3):723-34 [7657100.001]
  • [Cites] Gastroenterology. 1995 Sep;109(3):999-1001 [7657131.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2015-21 [9164213.001]
  • [Cites] Int J Cancer. 1998 Mar 2;75(5):767-73 [9495247.001]
  • [Cites] Int J Cancer. 1999 Feb 19;84(1):28-32 [9988228.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1003-7 [10070955.001]
  • [Cites] Pathol Int. 1999 Jan;49(1):55-61 [10227725.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):874-9 [15681533.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Jun;132(6):363-75 [16447040.001]
  • [Cites] World J Gastroenterol. 2006 Jun 28;12(24):3803-9 [16804962.001]
  • [Cites] J Natl Cancer Inst. 2006 Oct 18;98(20):1445-52 [17047193.001]
  • [Cites] Mutat Res. 2000 Jul 20;452(1):83-90 [10894894.001]
  • [Cites] Mod Pathol. 2000 Oct;13(10):1055-9 [11048797.001]
  • [Cites] Oncology. 2001;61(1):1-9 [11474241.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Sep;32(1):50-8 [11477661.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):592-8 [11522743.001]
  • [Cites] Oncology. 2001;61(3):212-20 [11574777.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2228-33 [11596042.001]
  • [Cites] Int J Cancer. 2002 Feb 10;97(5):562-6 [11807778.001]
  • [Cites] Int J Cancer. 2002 May 20;99(3):336-43 [11992401.001]
  • [Cites] Histopathology. 2002 Jul;41(1):56-64 [12121238.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):611-8 [12163385.001]
  • [Cites] Gastric Cancer. 2004;7(1):46-53 [15052440.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3082-90 [15131047.001]
  • [Cites] Br J Cancer. 2004 Oct 4;91(7):1342-8 [15354218.001]
  • [Cites] Gan. 1968 Jun;59(3):251-8 [5726267.001]
  • [Cites] J Histochem Cytochem. 1981 Apr;29(4):577-80 [6166661.001]
  • [Cites] Gastroenterology. 1984 Mar;86(3):461-7 [6693012.001]
  • [Cites] Clin Exp Immunol. 1984 Feb;55(2):319-32 [6365376.001]
  • [Cites] J Clin Pathol. 1985 Sep;38(9):1002-6 [2931454.001]
  • [Cites] Hum Pathol. 1986 May;17(5):482-7 [3699811.001]
  • [Cites] Cancer. 1987 Sep 1;60(5):1094-8 [3607726.001]
  • [Cites] Int J Cancer. 1988 Feb 15;41(2):184-97 [3338870.001]
  • [Cites] Hum Pathol. 1988 Aug;19(8):942-8 [3402983.001]
  • [Cites] Acta Pathol Jpn. 1990 Jul;40(7):494-504 [2220396.001]
  • [Cites] CA Cancer J Clin. 1991 Jan-Feb;41(1):19-36 [1984806.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Hum Pathol. 1991 Nov;22(11):1158-61 [1743701.001]
  • [Cites] Int J Cancer. 1992 Jan 21;50(2):202-7 [1730514.001]
  • [Cites] Cancer. 1992 Mar 1;69(5):1088-93 [1739905.001]
  • [Cites] J Am Coll Surg. 1995 May;180(5):577-82 [7749534.001]
  • (PMID = 17262083.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2360051
  •  go-up   go-down


42. Jørgensen JT: Targeted HER2 treatment in advanced gastric cancer. Oncology; 2010;78(1):26-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted HER2 treatment in advanced gastric cancer.
  • Amplification of the HER2 gene and over-expression of the HER2 protein in gastric cancer have been shown in a large number of studies.
  • Preclinical in vitro and in vivo studies have demonstrated that both trastuzumab and lapatinib are effective in different gastric cancer models and have thus lead to the initiation of clinical studies.
  • In the first phase III study, the ToGA trial, HER2-positive patients with advanced gastroesophageal and gastric adenocarcinoma were randomized to receive 5-fluorouracil/capecitabine and cisplatin either alone or in combination with trastuzumab.
  • It is expected that the encouraging results from the ToGA trial will have an immediate impact on the management of patients and that routine HER2 testing of patients with advanced gastric cancer will be initiated within a relatively short period of time.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms / drug therapy. Genes, erbB-2 / genetics. Receptor, ErbB-2 / biosynthesis. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20185938.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Quinazolines; 0VUA21238F / lapatinib; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


43. Vasudevan B: An unusual case of capecitabine hyperpigmentation: Is hyperpigmentation a part of hand-foot syndrome or a separate entity? Indian J Pharmacol; 2010 Oct;42(5):326-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 59-year-old man with adenocarcinoma of stomach was prescribed capecitabine as adjuvant chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncol Nurs Forum. 1999 May;26(4):753-62 [10337653.001]
  • [Cites] J Cutan Pathol. 1999 Jul;26(6):287-94 [10472757.001]
  • [Cites] Cancer Invest. 2002;20(1):3-10 [11853000.001]
  • [Cites] Ann Oncol. 2002 Apr;13(4):566-75 [12056707.001]
  • [Cites] Cutan Ocul Toxicol. 2008;27(4):311-5 [19037763.001]
  • [Cites] Ann Intern Med. 1984 Dec;101(6):798-9 [6497196.001]
  • [Cites] Cutis. 2004 Feb;73(2):101-6 [15027515.001]
  • [Cites] Clin Ther. 2005 Jan;27(1):23-44 [15763604.001]
  • [Cites] Korean J Intern Med. 2007 Jun;22(2):109-12 [17616027.001]
  • [Cites] Indian J Dermatol. 2008 Jan;53(1):43-4 [19967024.001]
  • (PMID = 21206630.001).
  • [ISSN] 1998-3751
  • [Journal-full-title] Indian journal of pharmacology
  • [ISO-abbreviation] Indian J Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2959221
  • [Keywords] NOTNLM ; Capecitabine / hand-foot syndrome / hyperpigmentation
  •  go-up   go-down


44. Roszczenko P, Jagusztyn-Krynicka EK: [Immunoproteomics of Helicobacter pylori--strategy for improvement of diagnostic tests and vaccine development]. Postepy Biochem; 2006;52(4):424-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Helicobacter pylori, Gram-negative spiral-shaped bacteria, member of epsilon-Proteobacteria, colonizes the gastric mucosa of humans. H. pylori has been identified as the causative agent of chronic inflammation, chronic gastritis and peptic ulceration and is considered a risk factor for the development of mucosa-associated lymphoid tissue lymphoma and adenocarcinoma of the stomach.
  • [MeSH-minor] Animals. Cats. Dogs. Gastritis / blood. Gastritis / diagnosis. Gastritis / immunology. Gastritis / microbiology. Humans. Mice. Peptic Ulcer / diagnosis. Peptic Ulcer / immunology. Peptic Ulcer / microbiology. Peptic Ulcer / prevention & control. Proteomics. Serum / chemistry. Serum / immunology. Stomach Neoplasms / diagnosis. Stomach Neoplasms / immunology. Stomach Neoplasms / microbiology. Stomach Neoplasms / prevention & control. Virulence Factors / immunology

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Immunization.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17536512.001).
  • [ISSN] 0032-5422
  • [Journal-full-title] Postepy biochemii
  • [ISO-abbreviation] Postepy Biochem.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / Antigens, Bacterial; 0 / Vaccines; 0 / Virulence Factors
  • [Number-of-references] 70
  •  go-up   go-down


45. Richards DA, Boehm KA, Anthony SP: Systemic therapy for gastric cancer and adenocarcinoma of the gastroesophageal junction: present status and future directions. Expert Opin Investig Drugs; 2007 Jul;16(7):1059-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic therapy for gastric cancer and adenocarcinoma of the gastroesophageal junction: present status and future directions.
  • Gastric cancer is a major worldwide problem and is a leading cause of death.
  • The incidence of distal gastric cancer is declining; however, there has been a rapid rise in the incidence of adenocarcinoma of the gastroesophageal junction, which is a more aggressive entity.
  • This review examines recent advances in the treatment of gastroesophageal junction adenocarcinoma and gastric cancer, newer agents and the potential agents that are in development, which can be logically applied to the treatment of this devastating disease.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drugs, Investigational. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17594189.001).
  • [ISSN] 1744-7658
  • [Journal-full-title] Expert opinion on investigational drugs
  • [ISO-abbreviation] Expert Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drugs, Investigational
  • [Number-of-references] 56
  •  go-up   go-down


46. Ward MH, Heineman EF, Markin RS, Weisenburger DD: Adenocarcinoma of the stomach and esophagus and drinking water and dietary sources of nitrate and nitrite. Int J Occup Environ Health; 2008 Jul-Sep;14(3):193-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the stomach and esophagus and drinking water and dietary sources of nitrate and nitrite.
  • We conducted a population-based case-control study of adenocarcinoma of the stomach and esophagus in Nebraska, U.S.A.
  • Among those who primarily used public water supplies (79 distal stomach, 84 esophagus, 321 controls), average nitrate levels were not associated with risk (highest versus lowest quartile: stomach OR=1.2, 95% CI [0.5-2.7]; esophagus OR=1.3, 95% CI [0.6-3.1]).
  • We observed the highest ORs for distal stomach cancer among those with higher water nitrate ingestion and higher intake of processed meat compared with low intakes of both; however, the test for positive interaction was not significant (p=0.213).
  • We did not observe this pattern for esophagus cancer.
  • Increasing intake of nitrate and nitrite from animal sources was associated with elevated ORs for stomach cancer and with a significant positive trend in risk of esophagus cancer (P-trend=0.325 and 0.015, respectively).
  • [MeSH-major] Adenocarcinoma / epidemiology. Diet / adverse effects. Esophageal Neoplasms / epidemiology. Nitrates / analysis. Nitrites / analysis. Stomach Neoplasms / epidemiology. Water Supply / analysis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Causes Control. 2001 Feb;12(2):163-72 [11246845.001]
  • [Cites] Nutr Cancer. 2007;59(2):185-91 [18001213.001]
  • [Cites] Nutr Cancer. 2002;42(1):33-40 [12235648.001]
  • [Cites] J Nutr. 2002 Nov;132(11 Suppl):3522S-3525S [12421881.001]
  • [Cites] Cancer Res. 1989 Jun 1;49(11):3117-21 [2720669.001]
  • [Cites] Epidemiology. 1990 Sep;1(5):349-56 [2078610.001]
  • [Cites] Epidemiology. 1990 Jan;1(1):58-64 [2081241.001]
  • [Cites] Arch Environ Health. 1992 Jul-Aug;47(4):292-4 [1497383.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1992 Sep-Oct;1(6):455-61 [1302557.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Jan-Feb;4(1):29-36 [7894321.001]
  • [Cites] Int J Cancer. 1997 Mar 28;71(1):14-9 [9096659.001]
  • [Cites] Br J Cancer. 1998 Jul;78(1):129-35 [9662263.001]
  • [Cites] Environ Health Perspect. 1998 Aug;106(8):459-63 [9681972.001]
  • [Cites] Int J Cancer. 1999 Mar 15;80(6):852-6 [10074917.001]
  • [Cites] Environ Health Perspect. 2005 Nov;113(11):1607-14 [16263519.001]
  • [Cites] J Occup Environ Med. 2005 Dec;47(12):1260-7 [16340707.001]
  • [Cites] Carcinogenesis. 2006 Jul;27(7):1497-501 [16571648.001]
  • [Cites] World J Gastroenterol. 2006 Jul 21;12(27):4296-303 [16865769.001]
  • [Cites] Lancet Oncol. 2006 Aug;7(8):628-9 [16900606.001]
  • [Cites] Environ Sci Technol. 2006 Dec 15;40(24):7834-40 [17256535.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Oct;10(10):1055-62 [11588131.001]
  • (PMID = 18686719.001).
  • [ISSN] 1077-3525
  • [Journal-full-title] International journal of occupational and environmental health
  • [ISO-abbreviation] Int J Occup Environ Health
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010125-12
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nitrates; 0 / Nitrites; 0 / Water Pollutants, Chemical
  • [Other-IDs] NLM/ NIHMS162722; NLM/ PMC2797489
  •  go-up   go-down


47. Chen J, Lou J, Liu T, Wu R, Dong X, He Q, Yang B, Hu Y: Synthesis and in-vitro antitumor activities of some mannich bases of 9-alkyl-1,2,3,4-tetrahydrocarbazole-1-ones. Arch Pharm (Weinheim); 2009 Mar;342(3):165-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All the compounds were tested for their cytotoxic activity in vitro against four human tumor cell lines including human non-small lung cancer cells (A549), human gastric adenocarcinoma (SGC), human colon cancer cell (HCT116), human myeoloid leukemia cells (K562), and one multi-drug resistant subline (KB-VCR).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212985.001).
  • [ISSN] 1521-4184
  • [Journal-full-title] Archiv der Pharmazie
  • [ISO-abbreviation] Arch. Pharm. (Weinheim)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carbazoles; 0 / Mannich Bases; 942-01-8 / 1,2,3,4-tetrahydrocarbazole
  •  go-up   go-down


48. D'Elios MM, Andersen LP: Inflammation, immunity, and vaccines for Helicobacter pylori. Helicobacter; 2009 Sep;14 Suppl 1:21-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Helicobacter pylori infects almost half of the population worldwide and represents the major cause of gastroduodenal diseases, such as duodenal and gastric ulcer, gastric adenocarcinoma, autoimmune gastritis, and B-cell lymphoma of mucosa-associated lymphoid tissue.
  • Helicobacter pylori induces the activation of a complex and fascinating cytokine and chemokine network in the gastric mucosa.
  • During the last year, significant progress was made on the road to the first efficient vaccine for H. pylori that will represent a novel and very important bullet against both infection and gastric cancer.
  • [MeSH-minor] Animals. Asthma / immunology. Asthma / microbiology. Gastric Mucosa / immunology. Gastric Mucosa / microbiology. Humans. Immunity

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19712164.001).
  • [ISSN] 1523-5378
  • [Journal-full-title] Helicobacter
  • [ISO-abbreviation] Helicobacter
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Vaccines
  • [Number-of-references] 84
  •  go-up   go-down


49. Zhao P, Li Y, Lu Y: Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma. BMC Cancer; 2010;10:218
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma.
  • BACKGROUND: The relationships between the expression of CD133, Ki-67 and prognosis in gastric adenocarcinoma are unknown and needs exploring.
  • METHODS: The samples of gastric adenocarcinoma from 336 Chinese patients with follow-up were analyzed for CD133 and Ki-67 protein expressions by immunohistochemical method.
  • RESULTS: CD133 was expressed in up to 57.4% (193/336) of this group of gastric carcinoma.
  • The expression of CD133 has a positive correlation with that of Ki-67 (r = 0.188, P = 0.001) in gastric adenocarcinoma.
  • CONCLUSIONS: It is suggested that CD133 may play an important role in the evolution of gastric adenocarcinoma and should be considered as a potential marker for the prognosis.
  • [MeSH-major] Adenocarcinoma / immunology. Antigens, CD / analysis. Biomarkers, Tumor / analysis. Glycoproteins / analysis. Ki-67 Antigen / analysis. Peptides / analysis. Stomach Neoplasms / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Asian Continental Ancestry Group. China. Female. Gastric Mucosa / immunology. Gastric Mucosa / pathology. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Risk Assessment. Time Factors. Up-Regulation. Young Adult

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Jan 1;60(1):18-21 [10646844.001]
  • [Cites] Br J Cancer. 2008 Oct 21;99(8):1285-9 [18781171.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Cell Cycle. 2004 Apr;3(4):414-5 [15004528.001]
  • [Cites] J Clin Pathol. 2004 Sep;57(9):965-9 [15333659.001]
  • [Cites] Blood. 1997 Dec 15;90(12):5013-21 [9389721.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Rocz Akad Med Bialymst. 2004;49 Suppl 1:64-6 [15638377.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Curr Opin Oncol. 2007 Jan;19(1):61-4 [17133114.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):687-8 [17151644.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Laryngoscope. 2007 Mar;117(3):455-60 [17334305.001]
  • [Cites] J Neurooncol. 2007 Nov;85(2):149-57 [17516028.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):123-9 [18172261.001]
  • [Cites] Ann Surg Oncol. 2008 Feb;15(2):638-48 [17932721.001]
  • [Cites] Br J Cancer. 2008 Apr 22;98(8):1389-97 [18349830.001]
  • [Cites] J Clin Invest. 2008 Jun;118(6):2021-4 [18497883.001]
  • [Cites] J Clin Invest. 2008 Jun;118(6):2111-20 [18497886.001]
  • [Cites] Br J Cancer. 2008 Jul 8;99(1):100-9 [18542072.001]
  • [Cites] Int J Clin Pract. 2008 Aug;62(8):1212-8 [18479363.001]
  • [Cites] Cancer Sci. 2008 Aug;99(8):1578-83 [18754869.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13427-32 [18765800.001]
  • [Cites] J Exp Clin Cancer Res. 2008;27:85 [19108713.001]
  • [Cites] Cancer Lett. 2009 Mar 18;275(2):185-93 [19026485.001]
  • [Cites] World J Gastroenterol. 2009 May 14;15(18):2258-64 [19437567.001]
  • [Cites] Expert Opin Ther Targets. 2009 Jul;13(7):823-37 [19530986.001]
  • [Cites] Eur J Cancer. 2009 Jul;45(11):2034-40 [19403300.001]
  • [Cites] BMC Cancer. 2009;9:221 [19583859.001]
  • [Cites] J Transl Med. 2009;7:56 [19583834.001]
  • [Cites] Cancer Treat Rev. 2009 Aug;35(5):403-8 [19369008.001]
  • [Cites] Histopathology. 2009 Sep;55(3):284-93 [19723143.001]
  • [Cites] Cancer Invest. 2009 Oct;27(8):844-50 [19626493.001]
  • [Cites] J Pathol. 2009 Dec;219(4):427-34 [19621338.001]
  • [Cites] Int J Cancer. 2010 Feb 15;126(4):950-8 [19676044.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • (PMID = 20487522.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Ki-67 Antigen; 0 / Peptides
  • [Other-IDs] NLM/ PMC2891633
  •  go-up   go-down


50. Gondim FA, de Oliveira GR, Thomas FP: Repeated syncopes, orthostatic hypotension and progressive visual impairment heralding the presentation of an occult gastric adenocarcinoma. Eur J Neurol; 2007 Jan;14(1):e44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repeated syncopes, orthostatic hypotension and progressive visual impairment heralding the presentation of an occult gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Hypotension, Orthostatic / diagnosis. Stomach Neoplasms / diagnosis. Syncope / diagnosis. Vision Disorders / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Disease Progression. Humans. Male. Middle Aged. Recurrence


51. Azagra JS, Ibañez-Aguirre JF, Goergen M, Ceuterick M, Bordas-Rivas JM, Almendral-López ML, Moreno-Elola A, Takieddine M, Guérin E: Long-term results of laparoscopic extended surgery in advanced gastric cancer: a series of 101 patients. Hepatogastroenterology; 2006 Mar-Apr;53(68):304-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of laparoscopic extended surgery in advanced gastric cancer: a series of 101 patients.
  • BACKGROUND/AIMS: The objective of our paper is to report on the remote results of patients with gastric cancer treated by mini-invasive surgery as a surgical tool with the "intention to treat with laparoscopy".
  • METHODOLOGY: Between June 1993 and January 2004, 101 patients comprising 72 men and 29 women with gastric adenocarcinoma were prospectively selected by two hospitals based on prior agreement (the CHU Charleroi, Belgium, and Zumárraga Hospital, the Basque Country, Spain).
  • Patients with adenocarcinoma of the cardia were excluded.
  • CONCLUSIONS: Laparoscopic gastrectomy with any kind of lymphadenectomy is a heavy but safe operation, and produces acceptable mortality and morbidity rates in patients with advanced gastric cancer in a general poor condition.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Gastrectomy. Laparoscopy. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16608045.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


52. Cangiano J, Centeno BA, Garrett CR, Cáceres W, de Jesús A, Lee JH, Pavía O, Jove R, Báez L, Sullivan DM, Muro-Cacho CA, Muñoz-Antonia T: Signal transduction proteins in tumors from Puerto Rican and Caucasian gastric adenocarcinoma patients: expression differences with potential for specific targeted therapies. Dig Dis Sci; 2008 Aug;53(8):2090-100
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signal transduction proteins in tumors from Puerto Rican and Caucasian gastric adenocarcinoma patients: expression differences with potential for specific targeted therapies.
  • Overexpression of the HER2/NEU gene is associated with aggressive behavior and poor prognosis in breast cancer, making the Her2/neu protein a directed-therapy target.
  • Importantly, Her2/neu expression was strong and diffuse in tumors with signet-ring morphology, while other histo-pathological subtypes showed higher intra-tumoral Her2/neu heterogeneity than typically observed in breast cancer.
  • Targeted therapies in gastric cancer directed at EGF-R and Hers-2/neu pathways warrant further investigation.


53. Kim HO, Hwang SI, Yoo CH, Kim H: Preoperative colonoscopy for patients with gastric adenocarcinoma. J Gastroenterol Hepatol; 2009 Nov;24(11):1740-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative colonoscopy for patients with gastric adenocarcinoma.
  • BACKGROUND AND AIM: In patients with gastric adenocarcinoma (GA), the most common double primary cancer is colorectal cancer.
  • The aim of the present study was to evaluate the necessity of preoperative colonoscopy in patients with GA who have no symptoms of colorectal disease or any past/family history of colorectal cancer.
  • MATERIALS: Colonoscopy was carried out in 205 patients before gastric surgery for treatment of GA.
  • The prevalence of colorectal neoplasms (CRN, adenoma and adenocarcinoma) was evaluated according to age, sex, body mass index (BMI) and stage, location and differentiation of GA.
  • Synchronous adenoma and adenocarcinoma were detected in 68 (33.2%) and four (2.0%) patients, respectively.
  • All of the GA patients with synchronous colorectal adenocarcinoma were older than 50 years.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Colonoscopy. Colorectal Neoplasms / pathology. Gastrectomy. Mass Screening / methods. Neoplasms, Second Primary. Stomach Neoplasms / pathology


54. Xiong ZJ, Lin P, Zhang J, Wang XJ, Wang Q, Ren JJ, Yang HL, Wang J, Wu YY: [Construction of eukaryotic expression plasmid pEGFP-ATP1B1 and its effect on gastric adenocarcinoma cell SGC-7901]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Mar;39(2):169-72, 176
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Construction of eukaryotic expression plasmid pEGFP-ATP1B1 and its effect on gastric adenocarcinoma cell SGC-7901].
  • Next pEGFP-ATP1B1 was transferred into gastric adenocarcinoma SGC-7901 cells by lipofectamine, then ATP1B1 mRNA expression in transfected cells was detected by real-time PCR, and also ATPase was detected after cell transfection, as well as the proliferation of such cells was measured by MTT.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Base Sequence. Cell Line, Tumor. Gene Expression. Humans. Microscopy, Fluorescence. Molecular Sequence Data. Plasmids / genetics. Recombinant Fusion Proteins / genetics. Recombinant Fusion Proteins / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Stomach Neoplasms / genetics. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology. Transfection / methods

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18630675.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Recombinant Fusion Proteins; 147336-22-9 / Green Fluorescent Proteins; EC 3.6.3.9 / ATP1B1 protein, human; EC 3.6.3.9 / Sodium-Potassium-Exchanging ATPase
  •  go-up   go-down


55. Younes M: What is the role of cytokeratins in Barrett/cardia differentiation? Arch Pathol Lab Med; 2005 Feb;129(2):181-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The importance of distinguishing between Barrett metaplasia and intestinal metaplasia of the gastric cardia is now accepted, and the management of each entity is quite different.
  • Patients with Barrett metaplasia are enrolled in surveillance programs, consisting of periodic endoscopy and biopsy, because of the known risk of developing adenocarcinoma of the esophagus.
  • Patients with intestinal metaplasia of the gastric cardia, however, are not currently enrolled in such programs, because this condition carries a low risk of developing adenocarcinoma of the gastric cardia.
  • However, because it may be associated with premalignant lesions elsewhere in the gastric mucosa, we propose that intestinal metaplasia of the gastric cardia may have the same clinical implication as Barrett metaplasia.
  • [MeSH-major] Barrett Esophagus / etiology. Cardia / pathology. Keratins / physiology. Metaplasia / etiology. Stomach Diseases / etiology

  • MedlinePlus Health Information. consumer health - Stomach Disorders.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15679416.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 68238-35-7 / Keratins
  • [Number-of-references] 16
  •  go-up   go-down


56. Vásquez D, Rodríguez JA, Theoduloz C, Calderon PB, Valderrama JA: Studies on quinones. Part 46. Synthesis and in vitro antitumor evaluation of aminopyrimidoisoquinolinequinones. Eur J Med Chem; 2010 Nov;45(11):5234-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cytotoxic activity of the aminoquinone derivatives was evaluated in vitro using the MTT colorimetric method against one normal cell line (MRC-5 lung fibroblasts) and four human cancer cell lines (AGS human gastric adenocarcinoma; SK-MES-1 human lung cancer cells, and J82 human bladder carcinoma; HL-60 human leukemia) in 72-h drug exposure assays.
  • Among the series, five compounds exhibited interesting antitumor activity against AGS human gastric adenocarcinoma and human lung cancer cells.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20828890.001).
  • [ISSN] 1768-3254
  • [Journal-full-title] European journal of medicinal chemistry
  • [ISO-abbreviation] Eur J Med Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinones
  •  go-up   go-down


57. Calişkan E, Sener M, Nursal TZ, Calişkan K, Türköz A, Bağiş T: Thoracic epidural anesthesia and analgesia for gastric resection at 26 week pregnant woman. Agri; 2006 Jul;18(3):20-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thoracic epidural anesthesia and analgesia for gastric resection at 26 week pregnant woman.
  • Gastric adenocarcinoma presenting during pregnancy is a rare condition and has a poor prognosis.
  • This report describes anaesthetic management of a woman who was diagnosed with gastric adenocarcinoma at 26 weeks' gestation.
  • [MeSH-major] Adenocarcinoma / diagnosis. Pain, Postoperative / prevention & control. Pregnancy Complications, Neoplastic / diagnosis. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Abdominal Pain / etiology. Adult. Anesthesia, Epidural / methods. Anesthesia, General / methods. Diagnosis, Differential. Female. Gastrectomy. Humans. Infant, Newborn. Nausea / etiology. Pregnancy. Pregnancy Trimester, Second. Vomiting / etiology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17089226.001).
  • [ISSN] 1300-0012
  • [Journal-full-title] Aǧrı : Ağrı (Algoloji) Derneği'nin Yayın organıdır = The journal of the Turkish Society of Algology
  • [ISO-abbreviation] Agri
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


58. Suttie SA, Park KG, Smith TA: [18F]2-fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil. Br J Cancer; 2007 Oct 8;97(7):902-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [18F]2-fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil.
  • Decreased tumour [(18)F]2-fluoro-2-deoxy-D-glucose ((18)FDG) incorporation is related to response however its significance at the cell level in gastro-oesophageal cancer and how it relates to cell death is unknown.
  • Here human gastric adenocarcinoma (AGS) cells were treated with lethal dose 10 and 50 (LD(10) and LD(50)), determined by using the MTT assay, of the three drugs, epirubicin, 5-fluorouracil and cisplatin, commonly used in the treatment of patients with gastro-oesophageal cancer. (18)FDG incorporation was determined after 48 and 72 h of treatment with each drug and related to drug-induced changes in glucose transport, hexokinase activity, cell cycle distribution and annexin V-PE binding (a measure of apoptosis).
  • Our results show that at the tumour cell level in gastric tumour cells, decreased (18)FDG incorporation and glucose transport, accompanies therapeutic growth inhibition. (18)FDG incorporation is particularly diminished in cells exhibiting apoptosis.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fluorodeoxyglucose F18 / pharmacokinetics. Stomach Neoplasms / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 2006 Sep;47(9):1525-30 [16954562.001]
  • [Cites] Science. 1956 Feb 24;123(3191):309-14 [13298683.001]
  • [Cites] J Clin Oncol. 1986 Mar;4(3):425-39 [3005521.001]
  • [Cites] Cancer Res. 1987 Feb 15;47(4):936-42 [3802100.001]
  • [Cites] Mol Cell Biol. 1987 Sep;7(9):3119-23 [2823120.001]
  • [Cites] J Clin Oncol. 1988 Oct;6(10):1653-64 [3049954.001]
  • [Cites] J Natl Cancer Inst. 1990 May 2;82(9):749-55 [1691303.001]
  • [Cites] Cancer Cells. 1990 Aug-Sep;2(8-9):275-80 [2223389.001]
  • [Cites] Biochem Pharmacol. 1990 Nov 15;40(10):2353-62 [2244936.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;30(3):189-92 [1628367.001]
  • [Cites] J Nucl Med. 1992 Nov;33(11):1972-80 [1432158.001]
  • [Cites] J Nucl Med. 1993 Mar;34(3):414-9 [8441032.001]
  • [Cites] Eur J Biochem. 1994 Feb 1;219(3):713-25 [8112322.001]
  • [Cites] J Nucl Med. 1995 Oct;36(10):1811-7 [7562048.001]
  • [Cites] Oncology. 1996 Jan-Feb;53(1):19-26 [8570126.001]
  • [Cites] Br J Biomed Sci. 1999;56(4):285-92 [10795374.001]
  • [Cites] Br J Biomed Sci. 2000;57(2):170-8 [10912295.001]
  • [Cites] Cell Mol Life Sci. 2000 Aug;57(8-9):1229-35 [11028915.001]
  • [Cites] J Nucl Med. 2000 Oct;41(10):1753-9 [11038008.001]
  • [Cites] J Nucl Med. 2001 Jan;42(1):170-5 [11197971.001]
  • [Cites] Mol Pharmacol. 2001 Apr;59(4):657-63 [11259608.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3058-65 [11408502.001]
  • [Cites] Nucl Med Commun. 2002 Jun;23(6):545-50 [12029209.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3515-20 [12067998.001]
  • [Cites] Biochemistry. 2002 Oct 22;41(42):12639-51 [12379106.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Nov;29(11):1462-9 [12397465.001]
  • [Cites] Mol Imaging Biol. 2003 Sep-Oct;5(5):337-46 [14630513.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4604-10 [14673049.001]
  • [Cites] J Nucl Med. 2004 Jan;45(1):56-68 [14734674.001]
  • [Cites] Nucl Med Biol. 2004 Jan;31(1):1-9 [14741565.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1500-7 [14977854.001]
  • [Cites] Int J Cancer. 2004 May 10;109(6):926-32 [15027127.001]
  • [Cites] Oncol Rep. 2004 Nov;12(5):955-65 [15492778.001]
  • [Cites] Anticancer Drugs. 2004 Sep;15(8):809-18 [15494644.001]
  • [Cites] J Nucl Med. 1978 Oct;19(10):1154-61 [214528.001]
  • [Cites] J Immunol Methods. 1983 Dec 16;65(1-2):55-63 [6606682.001]
  • [Cites] Trends Neurosci. 2005 Mar;28(3):117-9 [15749163.001]
  • [Cites] J Nucl Med. 2005 Apr;46(4):675-82 [15809491.001]
  • [Cites] Hepatogastroenterology. 2005 Mar-Apr;52(62):486-90 [15816463.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Jun;32(6):660-7 [15660258.001]
  • [Cites] J Nucl Med. 2006 Apr;47(4):603-8 [16595493.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] Biochem J. 1996 Feb 1;313 ( Pt 3):957-62 [8611181.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):1164-7 [8640778.001]
  • [Cites] Nucl Med Biol. 1996 May;23(4):533-41 [8832712.001]
  • [Cites] Radiat Res. 1997 Jun;147(6):729-34 [9189172.001]
  • [Cites] J Surg Oncol. 1997 Jun;65(2):106-10 [9209521.001]
  • [Cites] Nucl Med Biol. 1994 Aug;21(6):835-45 [9234333.001]
  • [Cites] J Nucl Med. 1997 Sep;38(9):1337-44 [9293783.001]
  • [Cites] J Bioenerg Biomembr. 1997 Aug;29(4):339-43 [9387094.001]
  • [Cites] Mol Cell Biol. 1998 Jan;18(1):378-87 [9418885.001]
  • [Cites] Br J Surg. 1998 Oct;85(10):1403-6 [9782025.001]
  • [Cites] Nucl Med Biol. 1998 Oct;25(7):593-7 [9804039.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):309-17 [10023697.001]
  • [Cites] J Nucl Med. 1999 Apr;40(4):556-65 [10210213.001]
  • [Cites] J Nucl Med. 1999 Jul;40(7):1085-90 [10405124.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4709-14 [10493529.001]
  • [Cites] Cancer Res. 1955 Feb;15(2):105-8 [14352196.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 Apr;34(4):441-3 [17072613.001]
  • (PMID = 17848947.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2360409
  •  go-up   go-down


59. Satti MB, Al-Quorain AA, Al-Gindan YM, Al Hamdan AA, Al-Idrissi HY: Gastric malignancy: clinicopathologic spectrum and relationship to Helicobacter pylori infection. Saudi J Gastroenterol; 2005 Sep;11(3):149-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric malignancy: clinicopathologic spectrum and relationship to Helicobacter pylori infection.
  • BACKGROUND: Upper gastrointestinal cancer particularly of stomach is a relatively frequent form of cancer.
  • Gastric H pylori infection has been implicated in the pathogenesis of both gastric carcinoma and gastric lymphoma.
  • Gastric carcinoma has been addressed by many articles in the Kingdom of Saudi Arabia (KSA) and the Middle East, while only a few addressed gastric lymphoma.
  • AIM OF THE STUDY: To investigate the relative frequency of gastric carcinoma and gastric lymphoma and their association with H pylori infection in endoscoped patients.
  • RESULTS: During the study period of 17 years (1983-1999), a total of 94 endoscopically-diagnosed, histologically-confirmed cases of gastric malignancy were identified.
  • Of these, there were 55 gastric adenocarcinoma and 39 gastric lymphoma.
  • H pylori was identified in the adjacent gastric mucosa in 18 of all cases of gastric adenocarcinoma and in 27 of the 39 cases of lymphoma.
  • CONCLUSION: The study demonstrates the comparatively high frequency of gastric lymphoma in this population and confirms the intimate association of H-pylori infection to both gastric adenocarcinoma and MALT-lymphoma.
  • Gastric lymphoma should always be considered in the differential diagnosis of gastric malignancy and the use of immunohistochemistry is essential for the differential diagnosis of some of these tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19861851.001).
  • [ISSN] 1998-4049
  • [Journal-full-title] Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
  • [ISO-abbreviation] Saudi J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


60. Salehi Z, Mollasalehi H, Jelodar MH, Kazemi M, Zahmatkesh R: The relationship between Helicobacter pylori infection and gastric adenocarcinoma in Northern Iran. Oncol Res; 2010;18(7):323-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship between Helicobacter pylori infection and gastric adenocarcinoma in Northern Iran.
  • Colonization of the human stomach with Helicobacter pylori induces chronic gastritis and is associated with the development of gastric and duodenal ulcers, gastric carcinoma, and gastric mucosa-associated lymphoid tissue lymphoma.
  • Infection with an H. pylori strain containing the cytotoxin-associated (cagA) gene (a marker for a pathogenicity island) may increase the risk of atrophic gastritis and gastric cancer.
  • The exact role of H. pylori in gastric carcinogenesis is still being investigated.
  • Hence, we assessed whether H. pylori infection is associated with the development of gastric adenocarcinoma in northern Iran.
  • Gastric biopsy specimens from 168 patients suffering from gastric adenocarcinoma, gastric ulcer, and non-ulcer dyspepsia were analyzed by means of the polymerase chain reaction. H. pylori was detected in the gastric mucosa of 34 (75.5%) gastric adenocarcinoma, 56 (88.8%) gastric ulcer, and 36 (60%) non-ulcer dyspepsia.
  • In patients with gastric adenocarcinoma, the cagA was less commonly found than those in noncancer patients (4/34 vs. 58/92, p < 0.05).
  • Our work suggests that although H. pylori infection is significantly associated with gastric adenocarcinoma in northern Iran, the cagA is not the dominant virulence in development of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / microbiology. Helicobacter Infections / microbiology. Helicobacter pylori / pathogenicity. Stomach Neoplasms / microbiology
  • [MeSH-minor] Adult. Aged. Antigens, Bacterial / genetics. Bacterial Proteins / genetics. Female. Gastritis / microbiology. Gastritis / surgery. Humans. Iran. Male. Middle Aged. Prognosis. Stomach Ulcer / genetics. Stomach Ulcer / microbiology. Stomach Ulcer / surgery

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20377133.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / Bacterial Proteins; 0 / cagA protein, Helicobacter pylori
  •  go-up   go-down


61. Khanna A, Böckelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, Junnila S, Murphy DJ, Evan GI, Haglund C, Westermarck J, Ristimäki A: MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst; 2009 Jun 3;101(11):793-805
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MYC-dependent regulation and prognostic role of CIP2A in gastric cancer.
  • However, the clinical relevance of CIP2A to human cancers had not been demonstrated, but the mechanism of its regulation and its clinical role in cancer were completely unknown.
  • METHODS: Tissue microarrays consisting of 223 gastric adenocarcinoma specimens were evaluated for the presence of CIP2A using immunohistochemistry, and the association of CIP2A expression with survival was assessed using Kaplan-Meier analysis.
  • The effects of MYC and CIP2A on each other's expression and on cell proliferation were investigated in several gastric cancer cell lines using small interfering RNAs to CIP2A and MYC and immunoblotting.
  • RESULTS: Expression of CIP2A protein was associated with reduced overall survival for gastric cancer patients with tumors 5 cm or smaller, with a 10-year overall survival in the CIP2A-immunopositive group of 8.1% as compared with 37.6% in the CIP2A-negative group (difference = 29.5%, 95% confidence interval = 12.5% to 46.5%, P = .001).
  • In gastric cancer cell lines, CIP2A depletion led to decreased proliferation and anchorage-independent growth of the cells, as well as to reduced stability and expression of MYC protein.
  • Finally, CIP2A and MYC immunopositivities were associated in gastric cancer specimens (P = .021).
  • CONCLUSIONS: CIP2A immunopositivity is a predictor of survival for some subgroups of gastric cancer patients.
  • CIP2A and MYC appear to be regulated in a positive feedback loop, wherein they promote each other's expression and gastric cancer cell proliferation.
  • [MeSH-major] Adenocarcinoma / chemistry. Autoantigens / analysis. Biomarkers, Tumor / analysis. Feedback, Physiological. Membrane Proteins / analysis. Proto-Oncogene Proteins c-myc / metabolism. Stomach Neoplasms / chemistry


62. Ashktorab H, Dashwood RH, Dashwood MM, Zaidi SI, Hewitt SM, Green WR, Lee EL, Daremipouran M, Nouraie M, Malekzadeh R, Smoot DT: H. pylori-induced apoptosis in human gastric cancer cells mediated via the release of apoptosis-inducing factor from mitochondria. Helicobacter; 2008 Dec;13(6):506-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] H. pylori-induced apoptosis in human gastric cancer cells mediated via the release of apoptosis-inducing factor from mitochondria.
  • METHODS: Human gastric adenocarcinoma (AGS) cells were incubated with a cagA-positive H. pylori strain for 0, 3, 6, and 24 hours and either total protein or cytoplasmic, nuclear, and mitochondrial membrane fractions were collected.
  • Active AIF staining was markedly increased in gastric mucosa from infected persons, compared to uninfected controls.
  • This is consistent with AIF activation that was found in the gastric mucosa of humans infected with H. pylori.
  • Hence, the balance between apoptosis and proliferation in these cells may be altered in response to injury caused by H. pylori infection, leading to an increased risk of cancer.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19166416.001).
  • [ISSN] 1523-5378
  • [Journal-full-title] Helicobacter
  • [ISO-abbreviation] Helicobacter
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK053713; United States / NIDDK NIH HHS / DK / DK53713; United States / NIDDK NIH HHS / DK / DK56664
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Apoptosis Inducing Factor
  •  go-up   go-down


63. Quiding-Järbrink M, Sundström P, Lundgren A, Hansson M, Bäckström M, Johansson C, Enarsson K, Hermansson M, Johnsson E, Svennerholm AM: Decreased IgA antibody production in the stomach of gastric adenocarcinoma patients. Clin Immunol; 2009 Jun;131(3):463-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased IgA antibody production in the stomach of gastric adenocarcinoma patients.
  • Gastric adenocarcinoma is closely associated with Helicobacter pylori infection.
  • To investigate a possible link between local antibody production and gastric tumors, we studied gastric B cell infiltration and local IgA production in patients with H. pylori induced gastric adenocarcinomas.
  • These studies showed that total and H. pylori-specific IgA antibody levels were substantially lower in gastric tissue from the cancer patients compared to those from asymptomatic H. pylori carriers.
  • However, serum IgA levels were similar in the cancer patients and asymptomatic carriers.
  • We conclude that patients suffering from gastric adenocarcinoma have a dramatically decreased local IgA production in the stomach compared to asymptomatic H. pylori infected individuals.
  • [MeSH-major] Adenocarcinoma / immunology. Gastric Mucosa / immunology. Helicobacter Infections / immunology. Immunoglobulin A / immunology. Stomach Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19249247.001).
  • [ISSN] 1521-7035
  • [Journal-full-title] Clinical immunology (Orlando, Fla.)
  • [ISO-abbreviation] Clin. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / Chemokines; 0 / Immunoglobulin A; EC 3.5.1.5 / Urease
  •  go-up   go-down


64. Sakellariou S, Liakakos T, Ghiconti I, Hadjikokolis S, Nakopoulou L, Pavlakis K: Immunohistochemical expression of P15 (INK4B) and SMAD4 in advanced gastric cancer. Anticancer Res; 2008 Mar-Apr;28(2A):1079-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of P15 (INK4B) and SMAD4 in advanced gastric cancer.
  • BACKGROUND: P15 (a cyclin- D- kinase inhibitor) and SMAD4 (a signal transducer of the TGF-beta pathway) are two closely related proteins which may have an important role in gastric carcinogenesis.
  • MATERIALS AND METHODS: Sixty-three gastric carcinomas were studied.
  • CONCLUSION: P15 gene silencing might be an important event in the tumorigenesis of gastric adenocarcinomas of the intestinal type.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p15 / metabolism. Smad4 Protein / metabolism. Stomach Neoplasms / metabolism


65. Baek KH, Jeon HM, Lee SS, Lim DJ, Oh KW, Lee WY, Rhee EJ, Han JH, Cha BY, Lee KW, Son HY, Kang SK, Kang MI: Short-term changes in bone and mineral metabolism following gastrectomy in gastric cancer patients. Bone; 2008 Jan;42(1):61-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short-term changes in bone and mineral metabolism following gastrectomy in gastric cancer patients.
  • This study investigated 46 patients undergoing gastrectomy for gastric adenocarcinoma and analyzed 36 patients (58.1+/-10.8 years, 24 men and 12 women) who had dual energy X-ray absorptiometry (DXA) performed before and 1 year after gastrectomy.
  • [MeSH-major] Bone Density / physiology. Bone and Bones / metabolism. Stomach Neoplasms / metabolism

  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Density.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17942383.001).
  • [ISSN] 8756-3282
  • [Journal-full-title] Bone
  • [ISO-abbreviation] Bone
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers; 0 / Collagen Type I; 0 / Parathyroid Hormone; 0 / Peptide Fragments; 0 / Peptides; 0 / Procollagen; 0 / collagen type I trimeric cross-linked peptide
  •  go-up   go-down


66. Jeong EG, Lee SH, Lee HW, Soung YH, Yoo NJ, Lee SH: Immunohistochemical and mutational analysis of FLASH in gastric carcinomas. APMIS; 2007 Aug;115(8):900-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical and mutational analysis of FLASH in gastric carcinomas.
  • Although such functions are important in cancer pathogenesis, little is known about the alterations of FLASH gene and FLASH protein expression in human cancers.
  • In this study, we analyzed the expression of FLASH protein in 60 gastric adenocarcinomas by immunohistochemistry.
  • We furthermore analyzed mutation of FLASH in exon 8, where two polyadenine tracts ((A)8 and (A)9) are present, by single-strand conformation polymorphism (SSCP) assay in 184 gastric adenocarcinomas.
  • By immunohistochemistry, FLASH protein expression in cancer cells was detected positively in 42 gastric carcinoma tissues (70%), whereas its expression in epithelial cells of normal gastric mucosa was shown as no or very weak intensity.
  • Mutational analysis detected one FLASH mutation in the gastric carcinomas (0.5%).
  • The increased expression of FLASH in the malignant gastric epithelial cells compared to the normal mucosal epithelial cells suggests that FLASH expression may play a role in gastric tumorigenesis.
  • Also, the data suggest that somatic mutation of FLASH is a rare event in gastric carcinomas.
  • [MeSH-major] Apoptosis Regulatory Proteins / analysis. Calcium-Binding Proteins / analysis. Mutation. Stomach Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17696945.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / CASP8AP2 protein, human; 0 / Calcium-Binding Proteins
  •  go-up   go-down


67. Aydin S, Ozercan IH, Dagli F, Aydin S, Dogru O, Celebi S, Akin O, Guzel SP: Ghrelin immunohistochemistry of gastric adenocarcinoma and mucoepidermoid carcinoma of salivary gland. Biotech Histochem; 2005 May-Aug;80(3-4):163-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ghrelin immunohistochemistry of gastric adenocarcinoma and mucoepidermoid carcinoma of salivary gland.
  • Ghrelin (G-HH) synthesized in several tissues including salivary and stomach glands stimulates appetite in humans by modulating neuropeptide Y neurons in the hypothalamic arcuate nucleus.
  • Loss of appetite is one of the most important symptoms of stomach cancer.
  • We conducted a study using immunohistochemistry to determine whether salivary glands and stomach cancer tissues produce ghrelin.
  • We determined that negative ghrelin immunohistochemistry discriminates tumors from normal tissues and may therefore further our understanding of the clinically important problem of reduced food intake and anorexia in cancer patients.
  • Radioimmunoassay analyses confirmed that cancer cells do not produce a G-HH peptide, whereas normal cells yield this peptide.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Mucoepidermoid / metabolism. Peptide Hormones / metabolism. Salivary Gland Neoplasms / metabolism. Salivary Glands / metabolism. Stomach Neoplasms / metabolism

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16298902.001).
  • [ISSN] 1052-0295
  • [Journal-full-title] Biotechnic & histochemistry : official publication of the Biological Stain Commission
  • [ISO-abbreviation] Biotech Histochem
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ghrelin; 0 / Peptide Hormones
  •  go-up   go-down


68. Mojtahedi A, Salehi R, Navabakbar F, Tamizifar H, Tavakkoli H, Duronio V: Evaluation of apoptosis induction using PARP cleavage on gastric adenocarcinoma and fibroblast cell lines by different strains of Helicobacter pylori. Pak J Biol Sci; 2007 Nov 15;10(22):4097-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of apoptosis induction using PARP cleavage on gastric adenocarcinoma and fibroblast cell lines by different strains of Helicobacter pylori.
  • Helicobacter pylori is one of the most common pathogens affecting humans and is the major environmental factor in the development of gastric cancer increasing from 4 to 6 folds the risk of its development.
  • Variations in cancer risk among H. pylori infected individuals may correlate to difference in H. pylori strains, variable host characteristics and specific interactions between host and microbial determinants.
  • [MeSH-major] Adenocarcinoma / microbiology. Apoptosis. Fibroblasts / microbiology. Helicobacter pylori / metabolism. Poly(ADP-ribose) Polymerases / metabolism. Stomach Neoplasms / microbiology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19090286.001).
  • [ISSN] 1028-8880
  • [Journal-full-title] Pakistan journal of biological sciences : PJBS
  • [ISO-abbreviation] Pak. J. Biol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / Bacterial Proteins; 0 / VacA protein, Helicobacter pylori; 0 / cagA protein, Helicobacter pylori; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases
  •  go-up   go-down


69. López-Tarruella Cobo S, Moreno Antón F, Sastre J, López García-Asenjo JA, Torres A, Díaz-Rubio E: Cuirasse skin metastases secondary to gastric adenocarcinoma. Clin Transl Oncol; 2005 Jun;7(5):213-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cuirasse skin metastases secondary to gastric adenocarcinoma.
  • Skin metastases from gastric adenocarcinomas are particularly rare, and represent 6% of the total in males and 1% in females.
  • We report, here, the case of a patient diagnosed with gastric adenocarcinoma with extensive subcutaneous infiltration of the abdominal wall, resulting in an abdominal cuirass.
  • [MeSH-major] Adenocarcinoma / secondary. Skin Neoplasms / secondary. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Invest. 2001;19(5):554-68 [11458821.001]
  • [Cites] Arch Anat Cytol Pathol. 1996;44(1):60-4 [8762894.001]
  • [Cites] Med Clin North Am. 1980 Sep;64(5):885-900 [7432046.001]
  • [Cites] Cancer. 1999 May 1;85(9):1894-902 [10223227.001]
  • [Cites] J Am Acad Dermatol. 1993 Aug;29(2 Pt 1):228-36 [8335743.001]
  • [Cites] Eur J Cancer Care (Engl). 2002 Jun;11(2):143-4 [12099951.001]
  • [Cites] An Med Interna. 2003 May;20(5):251-3 [12831300.001]
  • [Cites] J Exp Clin Cancer Res. 2001 Jun;20(2):297-9 [11484991.001]
  • [Cites] Int J Cancer. 2002 Apr 20;98(6):833-7 [11948459.001]
  • [Cites] Radiat Med. 1989 Mar-Apr;7(2):95-104 [2477873.001]
  • [Cites] Cancer. 1965 Jul;18:907-15 [14308240.001]
  • [Cites] Cancer. 1990 May 1;65(9):2086-90 [2372774.001]
  • [Cites] Eur J Dermatol. 2002 Jan-Feb;12(1):85-7 [11809606.001]
  • [Cites] Arch Dermatol. 1972 Jun;105(6):862-8 [5030236.001]
  • (PMID = 15960933.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


70. Fu S, Lu JJ, Zhang Q, Yang Z, Peng L, Xiong F: Intraoperative radiotherapy combined with adjuvant chemoradiotherapy for locally advanced gastric adenocarcinoma. Int J Radiat Oncol Biol Phys; 2008 Dec 1;72(5):1488-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative radiotherapy combined with adjuvant chemoradiotherapy for locally advanced gastric adenocarcinoma.
  • PURPOSE: To evaluate the efficacy of intraoperative radiotherapy (IORT) followed by concurrent chemotherapy and external beam RT (EBRT) in the treatment of locally advanced gastric adenocarcinoma.
  • METHODS AND MATERIALS: A total of 97 consecutive and nonselected patients with newly diagnosed Stage T3, T4, or N+ adenocarcinoma of the stomach underwent gastrectomy with D2 lymph node dissection between March 2003 and October 2005.
  • CONCLUSIONS: Radical gastrectomy with D2 lymph node dissection and IORT followed by adjuvant chemoradiotherapy appeared to be feasible and well-tolerated in the treatment of locally advanced gastric cancer.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Radiotherapy / methods. Stomach Neoplasms / radiotherapy. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18538489.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


71. Gandhi K, Parikh P, Aronow WS, Desai H, Amin H, Sharma M, Rubinstein A: A case of explosive progression of hepatocellular carcinoma in a patient with common variable immunodeficiency (CVID). J Gastrointest Cancer; 2010 Dec;41(4):281-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: While it is well known that patients with common variable immunodeficiency (CVID) are predisposed to various malignancies, primarily non-Hodgkin's lymphoma and gastric carcinomas, to our knowledge no cases of hepatocellular carcinoma have been reported in the absence of preexisting liver disease.
  • The patient was on prophylactic intravenous gammaglobulin and had received several years earlier a course of rituximab for an autoimmune disorder.
  • CONCLUSIONS: Although patients with CVID are predisposed to malignancies such as lymphoma and adenocarcinoma of the stomach, rapidly progressive hepatocellular carcinoma in the absence of any preexisting liver disease has not been described.

  • Genetic Alliance. consumer health - Common Variable Immunodeficiency.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Arch Allergy Immunol. 2009;150(4):311-24 [19571563.001]
  • [Cites] J Clin Immunol. 2007 May;27(3):308-16 [17510807.001]
  • [Cites] Clin Exp Med. 2004 Apr;3(4):211-7 [15103511.001]
  • [Cites] J Intern Med. 1996 Aug;240(2):99-102 [8810936.001]
  • [Cites] Hepatol Res. 2008 Apr;38(4):415-20 [18021227.001]
  • [Cites] Clin Immunol. 1999 Dec;93(3):190-7 [10600329.001]
  • [Cites] Clin Immunol. 1999 Jul;92(1):34-48 [10413651.001]
  • [Cites] Q J Med. 1993 Jan;86(1):31-42 [8438047.001]
  • [Cites] Ann Allergy Asthma Immunol. 2005 May;94(5 Suppl 1):S1-63 [15945566.001]
  • [Cites] Lancet. 2008 Aug 9;372(9637):489-502 [18692715.001]
  • [Cites] Eur J Pediatr. 1996 Jul;155(7):532-4 [8831072.001]
  • [Cites] Curr Opin Genet Dev. 2007 Jun;17(3):201-12 [17467261.001]
  • [Cites] Lancet. 1985 Feb 2;1(8423):263-6 [2857327.001]
  • [Cites] Clin Exp Immunol. 2002 Dec;130(3):495-500 [12452841.001]
  • [Cites] Am J Hematol. 2002 Mar;69(3):171-8 [11891803.001]
  • [Cites] J Clin Immunol. 1987 Jul;7(4):294-9 [3611296.001]
  • (PMID = 20473587.001).
  • [ISSN] 1941-6636
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunologic Factors
  •  go-up   go-down


72. Enarsson K, Johnsson E, Lindholm C, Lundgren A, Pan-Hammarström Q, Strömberg E, Bergin P, Baunge EL, Svennerholm AM, Quiding-Järbrink M: Differential mechanisms for T lymphocyte recruitment in normal and neoplastic human gastric mucosa. Clin Immunol; 2006 Jan;118(1):24-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential mechanisms for T lymphocyte recruitment in normal and neoplastic human gastric mucosa.
  • Worldwide, gastric adenocarcinoma (GC) is the second most common cause of death from malignant disease.
  • [MeSH-major] Adenocarcinoma / immunology. Cell Movement / immunology. Gastric Mucosa / immunology. Receptors, Lymphocyte Homing / immunology. Stomach Neoplasms / immunology. T-Lymphocytes / immunology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16157508.001).
  • [ISSN] 1521-6616
  • [Journal-full-title] Clinical immunology (Orlando, Fla.)
  • [ISO-abbreviation] Clin. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / CXCR3 protein, human; 0 / Immunoglobulins; 0 / L-selectin counter-receptors; 0 / LPL binding proteins, human; 0 / MADCAM1 protein, human; 0 / Membrane Proteins; 0 / Mucoproteins; 0 / Receptors, CXCR3; 0 / Receptors, Cell Surface; 0 / Receptors, Chemokine; 0 / Receptors, Lymphocyte Homing
  •  go-up   go-down


73. Leys CM, Nomura S, LaFleur BJ, Ferrone S, Kaminishi M, Montgomery E, Goldenring JR: Expression and prognostic significance of prothymosin-alpha and ERp57 in human gastric cancer. Surgery; 2007 Jan;141(1):41-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and prognostic significance of prothymosin-alpha and ERp57 in human gastric cancer.
  • PURPOSE: Prothymosin-alpha and ERp57 were previously identified as markers for gastric metaplasia in a mouse model of Helicobacter-induced gastric metaplasia and neoplasia.
  • In this paper we assess whether the expression of these putative biomarkers in humans is correlated with gastric metaplasia and adenocarcinoma and clinical outcomes.
  • METHODS: Eight tissue microarrays, containing 749 paraffin-embedded tissue cores from 164 gastric cancer patients, were stained for prothymosin-alpha and ERp57 by horseradish peroxidase immunohistochemical techniques.
  • RESULTS: Prothymosin-alpha stained a significantly higher percentage of nuclei in cancer and metastases compared with normal gastric mucosa.
  • ERp57 staining was significantly decreased in cancer and metastases compared with both normal gastric mucosa and metaplasias.
  • CONCLUSIONS: These results suggest that although prothymosin-alpha is overexpressed in gastric adenocarcinoma, it is not associated with alterations in survival.
  • In contrast, loss of ERp57 expression correlated with more aggressive disease and could provide useful prognostic information for gastric cancer patients.
  • [MeSH-major] Protein Disulfide-Isomerases / metabolism. Protein Precursors / metabolism. Stomach Neoplasms / metabolism. Thymosin / analogs & derivatives
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Down-Regulation. Endoplasmic Reticulum / metabolism. Humans. Immunohistochemistry. Metaplasia / metabolism. Molecular Chaperones / metabolism. Prognosis. Protein Array Analysis. Retrospective Studies. Stomach / metabolism. Stomach / pathology. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17188166.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P50 CA95103; United States / NCI NIH HHS / CA / CA67108; United States / NCI NIH HHS / CA / K12 CA090625; United States / NCI NIH HHS / CA / P50 CA62924
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Molecular Chaperones; 0 / Protein Precursors; 0 / prothymosin alpha; 61512-21-8 / Thymosin; EC 5.3.4.1 / Protein Disulfide-Isomerases; EC 5.3.4.1. / PDIA3 protein, human
  •  go-up   go-down


74. Macdonald JS: Role of post-operative chemoradiation in resected gastric cancer. J Surg Oncol; 2005 Jun 1;90(3):166-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of post-operative chemoradiation in resected gastric cancer.
  • The curative management of gastric adenocarcinoma depends upon complete resection of the primary tumor.
  • In patients with lymph node metastases in the resected specimen, the relapse and death rates from recurrent cancer are at least 70%-80%.
  • Intergroup study (INT-0116) demonstrated that combined chemoradiation following complete gastric resection improves median time to relapse (30 vs. 19 months, P < 0.0001) and overall survival (35 vs. 28 months, P = 0.01).
  • Future advances in the therapy of resectable gastric cancer may come from studies of pre-operative neoadjuvant chemoradiation and the application of targeted therapies such as growth receptor antagonists and anti-angiogenesis agents.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Gastrectomy. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc
  • [CommentIn] J Surg Oncol. 2005 Jun 1;90(3):171-3; discussion 173 [15895446.001]
  • (PMID = 15895449.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Number-of-references] 17
  •  go-up   go-down


75. Coelho-Prabhu N, Levy MJ, Baron TH: Successful transgastric drainage of a large mucinous adenocarcinoma of the stomach for palliation of malignant gastric luminal obstruction. Gastrointest Endosc; 2009 Apr;69(4):e23-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful transgastric drainage of a large mucinous adenocarcinoma of the stomach for palliation of malignant gastric luminal obstruction.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / complications. Cystadenocarcinoma, Mucinous / therapy. Drainage / methods. Gastric Outlet Obstruction / etiology. Gastric Outlet Obstruction / therapy. Palliative Care. Stomach Neoplasms / complications. Stomach Neoplasms / therapy
  • [MeSH-minor] Adult. Humans. Male. Remission Induction. Stomach

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19152898.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Sousa H, Pinto-Correia AL, Medeiros R, Dinis-Ribeiro M: Epstein-Barr virus is associated with gastric carcinoma: the question is what is the significance? World J Gastroenterol; 2008 Jul 21;14(27):4347-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus is associated with gastric carcinoma: the question is what is the significance?
  • AIM: To examine the possible role of the Epstein-Barr Virus (EBV) in the development of gastric adenocarcinoma (GC).
  • It is unclear whether EBV is involved in GC development or is a consequence of gastric inflammation secondary to immunosuppressive treatments.
  • RESULTS: The present study showed that the worldwide crude prevalence of EBV in gastric adenocarcinoma was 8.29%.
  • CONCLUSION: The present review has demonstrated a high prevalence of EBV in gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / virology. Herpesvirus 4, Human / metabolism. Immunosuppressive Agents / pharmacology. Stomach Neoplasms / pathology. Stomach Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncol Rep. 2003 Jul-Aug;10(4):1059-62 [12792770.001]
  • [Cites] J Med Virol. 2002 Nov;68(3):384-9 [12226826.001]
  • [Cites] Nat Rev Immunol. 2003 Oct;3(10):801-12 [14523386.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):803-21 [14871955.001]
  • [Cites] Gene. 2004 Oct 27;341:1-17 [15474284.001]
  • [Cites] Oncol Rep. 2004 Nov;12(5):1093-8 [15492798.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]
  • [Cites] Mod Pathol. 1990 May;3(3):377-80 [2163534.001]
  • [Cites] Am J Pathol. 1991 Sep;139(3):469-74 [1653517.001]
  • [Cites] Am J Pathol. 1992 Apr;140(4):769-74 [1314023.001]
  • [Cites] Lab Invest. 1994 Jul;71(1):73-81 [8041121.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):9131-5 [8090780.001]
  • [Cites] Int J Cancer. 1995 Mar 3;60(5):642-4 [7860138.001]
  • [Cites] Hum Pathol. 1995 Mar;26(3):267-71 [7890276.001]
  • [Cites] J Clin Gastroenterol. 1995 Apr;20(3):253-4 [7797839.001]
  • [Cites] J Virol. 1997 Jul;71(7):5688-91 [9188650.001]
  • [Cites] Int J Cancer. 1997 Dec 10;73(6):786-9 [9399652.001]
  • [Cites] Immunity. 1998 Sep;9(3):395-404 [9768759.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1 [10200776.001]
  • [Cites] World J Gastroenterol. 2005 Feb 7;11(5):629-33 [15655811.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Exp Clin Cancer Res. 2005 Mar;24(1):49-54 [15943031.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):581-92 [17287242.001]
  • [Cites] Annu Rev Pathol. 2006;1:375-404 [18039120.001]
  • [Cites] Cancer Res. 2000 May 15;60(10):2745-8 [10825150.001]
  • [Cites] Mol Pathol. 2000 Oct;53(5):255-61 [11091849.001]
  • [Cites] Methods Mol Biol. 2001;174:103-10 [11357631.001]
  • [Cites] Int J Cancer. 2001 Nov15;94(4):527-30 [11745439.001]
  • [Cites] J Clin Pathol. 2002 Sep;55(9):669-75 [12194996.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5108-21 [12910248.001]
  • (PMID = 18666324.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  • [Number-of-references] 31
  • [Other-IDs] NLM/ PMC2731187
  •  go-up   go-down


77. Jovanović I, Alempijević T, Milosavljević T, Popović D, Bjelović M, Micev M, Pesko P: [Clinicopathological characteristics of Barrett's carcinoma, cardia carcinoma type II and distal gastric carcinoma: influence of observed parameters on the five-year postoperative survival of patients]. Srp Arh Celok Lek; 2009 May-Jun;137(5-6):249-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological characteristics of Barrett's carcinoma, cardia carcinoma type II and distal gastric carcinoma: influence of observed parameters on the five-year postoperative survival of patients].
  • INTRODUCTION In the past two decades, the increased frequency of distal esophageal adenocarcinoma, esophagogastric junction and proximal gastric adenocarcinoma has been observed.
  • The vast majority of these tumours are diagnosed in advanced stages, when the prognosis is poorer than in other gastric cancers.
  • OBJECTIVE: The aim of our study was to analyze the demographic and clinicopathological characteristics of patients operated on for Barrett's, cardia and distal gastric adenocarcinomas, as well as to study the influence of manifestations of each cancerogenetic indication on the studied clinicopathological parameters and to analyze the 5-year survival rate of patients surgically treated for cardia adenocarcinoma in relation to the patients operated on for distal gastric adenocarcinoma.
  • In the patients operated on for Barrett's and cardia cancers, the tumours invaded more deeply the wall layers, i.e. they were significantly more invasive than the distal gastric tumour.
  • The lymph node involvement was present in 87.5% of patients with Barrett's cancer, in 80% with cardia cancer and in 87% with distal gastric cancer.
  • The 3-year survival rate of patients operated on for cardia cancer was 47.4% and the 5-year survival rate was 31.6%, while the 3-year survival rate of patients operated on for distal gastric cancer was 46.2% and the 5-year survival rate was 34.6%.
  • Singly, the patients' gender, cancer type and the degree of tumour differentiation had no influence on the length of patients' postsurgical survival rate.
  • CONCLUSION: At the time of diagnosis cardia cancer and cancers developed at the location of the Barrett's oesophagus, developed significant deeper per continuitatem than gastric cancer.
  • There were no other differences in regard to the analyzed clinicopathological parameters among the tumours of these three locations, and there was no difference between the 3-year and 5-year survival rate between the patients operated on for gastric cancer and cardia cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / complications. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19594065.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


78. Stewart JH 4th, Shen P, Levine EA: Intraperitoneal hyperthermic chemotherapy: an evolving paradigm for the treatment of peritoneal surface malignancies. Expert Rev Anticancer Ther; 2008 Nov;8(11):1809-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Unfortunately, advanced colorectal cancer is often present at the time the disease is diagnosed.
  • Although the first clinical series of peritoneal perfusion were small, Japanese trials, which utilized IPHC for prophylaxis in patients with gastric adenocarcinoma, Fujimoto was the first to report an improvement in survival for established gastric cracinomatosis.
  • [MeSH-major] Chemotherapy, Cancer, Regional Perfusion / trends. Hyperthermia, Induced / trends. Peritoneal Neoplasms / therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18983241.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K08 CA131482
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 75
  •  go-up   go-down


79. Bircan HA, Bircan S, Oztürk O, Ozyurt S, Sahin U, Akkaya A: Mediastinal tuberculous lymphadenitis with anthracosis as a cause of vocal cord paralysis. Tuberk Toraks; 2007;55(4):409-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis of anthracosis and mediastinal tuberculous lymphadenitis was made and the patients put on antituberculous treatment.
  • But she unfortunately died in the second month of the treatment because of the abdominal complication of gastric adenocarcinoma operation.
  • [MeSH-major] Mediastinal Diseases / diagnosis. Tuberculosis, Lymph Node / diagnosis. Vocal Cord Paralysis / diagnosis
  • [MeSH-minor] Aged. Cough / etiology. Diagnosis, Differential. Female. Hoarseness / etiology. Humans. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - paralysis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18224512.001).
  • [ISSN] 0494-1373
  • [Journal-full-title] Tüberküloz ve toraks
  • [ISO-abbreviation] Tuberk Toraks
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


80. Chen H, Zhang S, Zhen K, Wang XF: [Relationship between the expression of occludin and tumor genesis and development in the gastric carcinoma]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2010 Oct;26(10):1008-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship between the expression of occludin and tumor genesis and development in the gastric carcinoma].
  • AIM: to investigate the expression of occludin mRNA and protein in the gastric cancer, to seek the relationship between the expression of occludin and tumor genesis and development.
  • METHODS: the expression of occludin was examined in the gastric carcinoma by immunohistochemical technique with the tissue microarray and by real time fluorescence quantitative PCR, and to study the association of occludin expression and clinicopathological features in the gastric adenocarcinomas.
  • RESULTS: the expression levels of occludin protein in the paraneoplastic normal gastric mucosa is obviously higher than that in the carcinoma(96.9% vs 85.4%, 84.6%, 89.2%, 78.5%)(P<0.05), the expression level in the gastric adenocarcinomas is related with the histologic differentiation and the grade of TNM (P<0.05).
  • The real time fluorescence quantitative PCR show that the expression of occludin mRNA in the gastric cancer is not obviously different from that in paracancerous tissues (P>0.05).
  • CONCLUSIONS: the expression levels of occludin protein in the gastric adenocarcinomas is negative correlation with tumor genesis and development.
  • [MeSH-major] Carcinoma / metabolism. Membrane Proteins / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20937238.001).
  • [ISSN] 1007-8738
  • [Journal-full-title] Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  • [ISO-abbreviation] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / OCLN protein, human; 0 / Occludin
  •  go-up   go-down


81. Wang M, Pan JY, Song GR, Chen HB, An LJ, Qu SX: Altered expression of estrogen receptor alpha and beta in advanced gastric adenocarcinoma: correlation with prothymosin alpha and clinicopathological parameters. Eur J Surg Oncol; 2007 Mar;33(2):195-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered expression of estrogen receptor alpha and beta in advanced gastric adenocarcinoma: correlation with prothymosin alpha and clinicopathological parameters.
  • AIMS: We aimed to investigate the sources of estrogen receptor alpha (ERalpha), estrogen receptor beta (ERbeta) and estimate the value of both ER subtypes in gastric adenocarcinoma and analyze the possible relationship of prothymosin alpha (ProTalpha) to ERs.
  • METHODS: ERs at the mRNA and protein levels in matched advanced gastric adenocarcinomas and surrounding non-cancerous tissues were examined by using reverse transcription-polymerase chain reaction and immunohistochemical (IHC) methods.
  • RESULTS: Both ERalpha and ERbeta mRNAs were detected in most of the cancer and matched normal tissues analyzed.
  • ERalpha immunoreactivity was only detected in poorly differentiated adenocarcinoma and ERalpha positive expression correlated with depth of invasion of the tumors.
  • Compared with non-cancerous tissues, gastric tumors showed decreased ERbeta expression and lost ERbeta.
  • Altered ERbeta in gastric adenocarcinoma correlated with decreased differentiation.
  • CONCLUSIONS: Altered expression of ERalpha and ERbeta in tumors compared with corresponding normal gastric tissues was more common in poorly differentiated adenocarcinomas and related to malignant properties, such as lymph node metastasis.
  • Decreased ERbeta and increased ProTalpha expression in advanced gastric adenocarcinoma indicated that ERbeta may play an anti-proliferation role which is opposed to the role of ProTalpha in gastric epithelium.
  • [MeSH-major] Adenocarcinoma. Estrogen Receptor alpha / genetics. Estrogen Receptor beta / genetics. Gene Expression Regulation, Neoplastic. Protein Precursors / genetics. RNA, Neoplasm / genetics. Stomach Neoplasms. Thymosin / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17046193.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / Protein Precursors; 0 / RNA, Neoplasm; 0 / prothymosin alpha; 61512-21-8 / Thymosin
  •  go-up   go-down


82. Sarbia M, Fritze F, Geddert H, von Weyhern C, Rosenberg R, Gellert K: Differentiation between pancreaticobiliary and upper gastrointestinal adenocarcinomas: is analysis of cytokeratin 17 expression helpful? Am J Clin Pathol; 2007 Aug;128(2):255-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation between pancreaticobiliary and upper gastrointestinal adenocarcinomas: is analysis of cytokeratin 17 expression helpful?
  • Metastatic adenocarcinoma of unknown primary site, eg, to lymph nodes, liver, or lung, may originate from many organs.
  • Microscopic differentiation of adenocarcinomas from the pancreaticobiliary and upper gastrointestinal tracts may be difficult because of shared histologic and immunohistologic features.
  • A high prevalence of cytokeratin (CK)17 expression in pancreaticobiliary adenocarcinoma was reported, and preliminary data indicate infrequent or missing expression in gastric adenocarcinoma.
  • The prevalence of CK17 expression in gastric cardiac and esophageal adenocarcinomas has not been studied.
  • We studied CK17 expression in tissue microarrays of 67 distal gastric, 71 gastric cardiac, and 46 esophageal adenocarcinomas and compared it with expression in 55 pancreatic, 23 extrahepatic bile duct, and 49 colorectal adenocarcinomas.
  • CK17 expression was as follows: pancreatic, 88%; bile duct, 59%; esophageal, 30%; distal gastric, 28%; gastric cardiac, 27%; and colorectal adenocarcinoma, 6%.
  • These differences were statistically significant for all tumor types except in comparisons of esophageal, cardiac, and distal gastric adenocarcinoma.
  • The prevalence of CK17 expression in pancreatic and extrahepatic bile duct adenocarcinomas is substantially higher than in upper gastrointestinal tract and colorectal adenocarcinomas.
  • However, in individual cases of adenocarcinoma of unknown primary site, CK17 results alone are insufficient to differentiate the analyzed tumor entities.
  • [MeSH-major] Adenocarcinoma / chemistry. Bile Duct Neoplasms / chemistry. Gastrointestinal Neoplasms / chemistry. Keratin-17 / analysis. Pancreatic Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638659.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Keratin-17
  •  go-up   go-down


83. Kikuchi H, Ohtsuki T, Koyano T, Kowithayakorn T, Sakai T, Ishibashi M: Death receptor 5 targeting activity-guided isolation of isoflavones from Millettia brandisiana and Ardisia colorata and evaluation of ability to induce TRAIL-mediated apoptosis. Bioorg Med Chem; 2009 Feb 1;17(3):1181-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we revealed that 1 sensitized TRAIL-resistant human gastric adenocarcinoma (AGS) cells to TRAIL-induced apoptosis by up-regulating the expression of DR5.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19124248.001).
  • [ISSN] 1464-3391
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Isoflavones; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Recombinant Fusion Proteins; 0 / TNF-Related Apoptosis-Inducing Ligand
  •  go-up   go-down


84. Lien HC, Lu YS, Shun CT, Yao YT, Chang WC, Cheng AL: Differential expression of glucocorticoid receptor in carcinomas of the human digestive system. Histopathology; 2008 Feb;52(3):314-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Consistently, GR expression was found in a high percentage of oesophageal squamous cell carcinomas (SCC) (98.1%) and hepatocellular carcinomas (HCC) (92.9%), but rarely in gastric adenocarcinomas (7.4%) and not at all in colorectal adenocarcinomas (0%).
  • The general lack of GR in adenocarcinomas contrasts with the high percentage of SCCs and HCCs expressing GR, and, along with the generation of chemoresistance by DEX, warrants prospective study of the effects of steroids on these cancers.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Basosquamous / metabolism. Carcinoma, Squamous Cell / metabolism. Digestive System Neoplasms / metabolism. Receptors, Glucocorticoid / metabolism

  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18269582.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Receptors, Glucocorticoid; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


85. Dalal KM, Woo Y, Kelly K, Galanis C, Gonen M, Fong Y, Coit DG: Detection of micrometastases in peritoneal washings of gastric cancer patients by the reverse transcriptase polymerase chain reaction. Gastric Cancer; 2008;11(4):206-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of micrometastases in peritoneal washings of gastric cancer patients by the reverse transcriptase polymerase chain reaction.
  • BACKGROUND: Gastric cancer patients with positive (+) peritoneal cytology have a prognosis similar to stage IV patients.
  • METHODS: Peritoneal washings were obtained prospectively from 34 patients with gastric adenocarcinoma undergoing staging laparoscopy and 6 patients undergoing laparoscopy for benign disease.
  • RESULTS: Pathologic stages for the gastric cancer patients were: stage I, 9 (27%); stage II, 7 (21%); stage III, 15 (44%); and stage IV, 3 (9%).
  • [MeSH-major] Adenocarcinoma / secondary. Peritoneal Cavity / pathology. Peritoneal Neoplasms / secondary. Reverse Transcriptase Polymerase Chain Reaction. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 2006 Feb;202(2):231-6 [16427547.001]
  • [Cites] Ann Surg Oncol. 2007 May;14 (5):1694-702 [17294072.001]
  • [Cites] Int J Cancer. 2006 Oct 15;119(8):1850-7 [16721789.001]
  • [Cites] Br J Obstet Gynaecol. 1989 May;96(5):574-9 [2604772.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):678-85 [12576435.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 23;313(4):931-7 [14706632.001]
  • [Cites] Cancer. 1978 Sep;42(3 Suppl):1412-8 [361200.001]
  • [Cites] Ann Surg Oncol. 2005 May;12(5):347-53 [15915368.001]
  • [Cites] Br J Surg. 2004 Apr;91(4):435-43 [15048743.001]
  • [Cites] Can J Otolaryngol. 1975;4(1):46-50 [1131725.001]
  • [Cites] Clin Chem. 1993 Apr;39(4):561-77 [8472349.001]
  • [Cites] J Gastrointest Surg. 2007 Dec;11(12):1598-605; discussion 1605-6 [17879123.001]
  • [Cites] Gastric Cancer. 2005;8(3):142-8 [16086116.001]
  • [Cites] Chin Med J (Engl). 2004 Aug;117(8):1210-7 [15361297.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):4158-63 [10632355.001]
  • [Cites] J Gastrointest Surg. 1998 May-Jun;2(3):244-9 [9841981.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):365-72 [17146744.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3406-11 [9779720.001]
  • [Cites] J Cancer Res Clin Oncol. 1984;108(2):236-8 [6470030.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8664-7 [11751382.001]
  • [Cites] Am J Dig Dis. 1978 Feb;23(2):129-33 [623075.001]
  • [Cites] Ann Surg Oncol. 2007 Oct;14(10):2702-13 [17653801.001]
  • [Cites] Semin Nucl Med. 1975 Jul;5(3):255-62 [1154032.001]
  • [Cites] Br J Surg. 2000 Feb;87(2):236-42 [10671934.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Surg Oncol. 1999 Oct;72(2):60-4; discussion 64-5 [10518099.001]
  • [Cites] J Surg Oncol. 1995 Aug;59(4):226-9 [7630168.001]
  • [Cites] Br J Surg. 1996 May;83(5):672-4 [8689216.001]
  • [Cites] J Clin Endocrinol Metab. 1981 Mar;52(3):457-62 [6893991.001]
  • [Cites] Int J Cancer. 1998 Aug 21;79(4):429-33 [9699538.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):499-506 [11923605.001]
  • (PMID = 19132482.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Inhibitor of Apoptosis Proteins; 0 / Keratin-20; 0 / MUC2 protein, human; 0 / Microtubule-Associated Proteins; 0 / Mucin-2; 0 / RNA, Messenger
  •  go-up   go-down


86. Oki M, Yamamoto H, Taniguchi H, Adachi Y, Imai K, Shinomura Y: Overexpression of the receptor tyrosine kinase EphA4 in human gastric cancers. World J Gastroenterol; 2008 Oct 7;14(37):5650-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of the receptor tyrosine kinase EphA4 in human gastric cancers.
  • AIM: To clarify the expression and role of Ephrin receptor A4 (EphA4) in gastric cancer in relation to clinicopathological characteristics and the expression of fibroblast growth factor receptor 1 (FGFR1) and ephrin ligands.
  • METHODS: Eleven gastric carcinoma cell lines, 24 paired surgical fresh specimens of gastric adenocarcinoma and adjacent nontumor tissue, 74 conventional formalin-fixed, paraffin-embedded tumor specimens, and 55 specimens spotted on tissue microarray (TMA) were analyzed.
  • RESULTS: Overexpression of EphA4 mRNA expression was observed in 8 (73%) of 11 gastric cancer cell lines and 10 (42%) of 24 gastric cancer tissues.
  • Overexpression of EphA4, analyzed by immunohistochemistry, was observed in 62 (48%) of 129 gastric cancer tissues.
  • Patients with EphA4-positive cancer had significantly shorter overall survival periods than did those with EphA4-negative cancer (P = 0.0008).
  • The mRNAs for ephrin ligands were coexpressed in various combinations in gastric cancer cell lines and cancer tissues.
  • Downregulation of EphA4 expression by siRNA in EphA4-overexpressing gastric cancer cell lines resulted in a significant decrease in cell growth.
  • CONCLUSION: Our results suggest that overexpression of EphA4 plays a role in gastric cancer.
  • [MeSH-major] Adenocarcinoma / enzymology. Receptor, EphA4 / metabolism. Stomach Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2007 Jan 11;26(2):308-11 [16819508.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10170-3 [16288001.001]
  • [Cites] Clin Chem. 2004 Mar;50(3):490-9 [14726470.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):5963-72 [15342375.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3645-50 [8033077.001]
  • [Cites] Int J Cancer. 1999 Jul 19;82(2):298-304 [10389767.001]
  • [Cites] Cancer Sci. 2005 Jan;96(1):42-7 [15649254.001]
  • [Cites] J Cancer Res Clin Oncol. 2000 Sep;126(9):519-28 [11003564.001]
  • [Cites] Oncogene. 2005 Nov 24;24(53):7946-52 [16007117.001]
  • [Cites] World J Gastroenterol. 2006 Jan 14;12(2):192-8 [16482617.001]
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):642-50 [16330025.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Apr;4(4):416-25 [16616344.001]
  • [Cites] World J Gastroenterol. 2006 Jun 7;12(21):3297-305 [16733844.001]
  • [Cites] Int J Oncol. 2006 Jul;29(1):163-8 [16773196.001]
  • [Cites] Nat Rev Cancer. 2006 Sep;6(9):714-27 [16929325.001]
  • [Cites] Cancer Sci. 2006 Nov;97(11):1211-6 [16965393.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):2007-15 [10854223.001]
  • [Cites] Nature. 2005 Jun 23;435(7045):1126-30 [15973414.001]
  • [Cites] Oncogene. 2000 Nov 20;19(49):5680-9 [11114748.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Jul;3(7):475-86 [12094214.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Jul;128(7):343-8 [12136247.001]
  • [Cites] Br J Cancer. 2003 Apr 7;88(7):1058-64 [12671705.001]
  • [Cites] Oncogene. 2005 Aug 25;24(36):5637-47 [16007213.001]
  • [Cites] J Cell Sci. 2003 Jul 15;116(Pt 14):2823-32 [12808016.001]
  • (PMID = 18837080.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Ephrins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; EC 2.7.10.1 / FGFR1 protein, human; EC 2.7.10.1 / Receptor, EphA4; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 1
  • [Other-IDs] NLM/ PMC2748198
  •  go-up   go-down


87. Lamb P, Sivashanmugam T, White M, Irving M, Wayman J, Raimes S: Gastric cancer surgery--a balance of risk and radicality. Ann R Coll Surg Engl; 2008 Apr;90(3):235-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric cancer surgery--a balance of risk and radicality.
  • INTRODUCTION: The aim of this study was to determine whether tailoring the extent of resection would allow radical gastric cancer surgery to be performed safely in a UK population.
  • PATIENTS AND METHODS: A total of 180 consecutive patients (median age 70 years; male:female ratio 2:1) undergoing resection for gastric adenocarcinoma with curative intent were studied.
  • CONCLUSIONS: By tailoring the extent of resection and balancing risk and radicality, gastric cancer surgery can be performed with low mortality in Western patients.
  • [MeSH-major] Adenocarcinoma / surgery. Gastrectomy / methods. Lymph Node Excision / methods. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2001 Feb;88(2):278-85 [11167881.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] Ann Surg Oncol. 2002 Nov;9(9):894-900 [12417512.001]
  • [Cites] BMJ. 2003 Nov 22;327(7425):1192-7 [14630753.001]
  • [Cites] Hepatogastroenterology. 2004 Jul-Aug;51(58):1225-8 [15239284.001]
  • [Cites] World J Surg. 1987 Aug;11(4):418-25 [3630186.001]
  • [Cites] BMJ. 1993 Sep 4;307(6904):591-6 [8401015.001]
  • [Cites] Lancet. 1995 Mar 25;345(8952):745-8 [7891484.001]
  • [Cites] Gut. 1995 May;36(5):684-90 [7797117.001]
  • [Cites] World J Surg. 1995 Jul-Aug;19(4):546-53 [7676699.001]
  • [Cites] Lancet. 1996 Apr 13;347(9007):995-9 [8606613.001]
  • [Cites] Ann Surg. 1997 Jun;225(6):678-83; discussion 683-5 [9230808.001]
  • [Cites] Surgery. 1998 May;123(5):573-8 [9591011.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):449-61 [9790335.001]
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • [Cites] Br J Cancer. 1999 Mar;79(9-10):1522-30 [10188901.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1099-102 [15931657.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1055-6 [16106468.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1103-9 [16106493.001]
  • [Cites] Br J Surg. 2006 May;93(5):559-63 [16607678.001]
  • [Cites] Surg Oncol. 2000 Jul;9(1):31-4 [11525304.001]
  • (PMID = 18430340.001).
  • [ISSN] 1478-7083
  • [Journal-full-title] Annals of the Royal College of Surgeons of England
  • [ISO-abbreviation] Ann R Coll Surg Engl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2430435
  •  go-up   go-down


88. Fakhrejahani E, Miyamoto A, Tanigawa N: Correlation between thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level and in vitro chemosensitivity to 5-fluorouracil, in relation to differentiation in gastric cancer. Cancer Chemother Pharmacol; 2007 Aug;60(3):437-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level and in vitro chemosensitivity to 5-fluorouracil, in relation to differentiation in gastric cancer.
  • PURPOSE: It has been suggested that the gene expression levels of thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) help in the prediction of the response to 5-fluorouracil (5-FU) in vivo and in vitro in gastric cancers.
  • METHODS: In this study, intratumoral TS and DPD gene expressions were evaluated with real time reverse transcriptional polymerase chain reaction technique to determine the correlation between the expression of these two genes and in vitro sensitivity to 5-FU, assessed by the histoculture drug response assay on 87 patients with gastric adenocarcinoma.
  • CONCLUSIONS: Different gene expression might be responsible for 5-FU sensitivity in gastric cancers of different histologic origin.
  • [MeSH-major] Dihydrouracil Dehydrogenase (NADP) / genetics. Fluorouracil / pharmacology. Gene Expression Regulation, Neoplastic / drug effects. RNA, Messenger / metabolism. Stomach Neoplasms / enzymology. Stomach Neoplasms / genetics. Thymidylate Synthase / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer Chemother Pharmacol. 2007 Aug;60(3):447
  • (PMID = 17377791.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 1.3.1.2 / Dihydrouracil Dehydrogenase (NADP); EC 2.1.1.45 / Thymidylate Synthase; U3P01618RT / Fluorouracil
  •  go-up   go-down


89. Huang JF, He J: [Clinical characteristics and prognostic factors in metachronous primary esophageal and gastric carcinomas]. Zhonghua Zhong Liu Za Zhi; 2008 Jul;30(7):545-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics and prognostic factors in metachronous primary esophageal and gastric carcinomas].
  • OBJECTIVE: To investigate the clinical characteristics and prognostic factors in metachronous squamous cell carcinoma of the esophagus and gastric adenocarcinoma.
  • METHODS: From July 1979 to March 2005, 27 patients with metachronous carcinomas of the esophagus and stomach were treated, and the data were retrospectively reviewed.
  • The clinical features were analyzed, which included sex, age, family history of cancers, TNM stages of the gastric and esophageal carcinomas, resection mode, chemotherapy and/or radiotherapy, and the sequence of the two carcinomas taking place.
  • CONCLUSION: Metachronous squamous cell carcinoma of the esophagus and gastric adenocarcinoma show distinct clinical characteristics.
  • [MeSH-major] Esophageal Neoplasms / surgery. Genetic Predisposition to Disease. Neoplasms, Second Primary / surgery. Stomach Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / surgery. Adenocarcinoma / therapy. Adult. Aged. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / surgery. Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant. Esophagectomy / methods. Female. Follow-Up Studies. Gastrectomy / methods. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19062726.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


90. Sýkora J, Pazdiora P, Varvarovská J, Pomahacová R, Stozický F, Siala K: [Current epidemiological and clinical issues regarding Helicobacter pylori infection in childhood]. Epidemiol Mikrobiol Imunol; 2006 Feb;55(1):3-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The main risk factor for acquiring the infection seems to be low socioeconomic status. H. pylori is associated with gastritis, duodenal ulcers, MALT lymphoma, and gastric adenocarcinoma.
  • However, the infection is often asymptomatic in children and the role of H. pylori infection in gastric manifestations is the subject of conflicting reports.
  • Methods for the diagnosis of H. pylori infection in children are subdivided into invasive and noninvasive.
  • [MeSH-minor] Child. Gastrointestinal Diseases / diagnosis. Gastrointestinal Diseases / drug therapy. Gastrointestinal Diseases / microbiology. Humans

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16528894.001).
  • [ISSN] 1210-7913
  • [Journal-full-title] Epidemiologie, mikrobiologie, imunologie : casopis Spolecnosti pro epidemiologii a mikrobiologii Ceské lékarské spolecnosti J.E. Purkyne
  • [ISO-abbreviation] Epidemiol Mikrobiol Imunol
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Czech Republic
  • [Number-of-references] 113
  •  go-up   go-down


91. Shinto O, Yashiro M, Toyokawa T, Nishii T, Kaizaki R, Matsuzaki T, Noda S, Kubo N, Tanaka H, Doi Y, Ohira M, Muguruma K, Sawada T, Hirakawa K: Phosphorylated smad2 in advanced stage gastric carcinoma. BMC Cancer; 2010;10:652
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phosphorylated smad2 in advanced stage gastric carcinoma.
  • BACKGROUND: Transforming growth factor β (TGFβ) receptor signaling is closely associated with the invasion ability of gastric cancer cells.
  • Although Smad signal is a critical integrator of TGFβ receptor signaling transduction systems, not much is known about the role of Smad2 expression in gastric carcinoma.
  • The aim of the current study is to clarify the role of phosphorylated Smad2 (p-Smad2) in gastric adenocarcinomas at advanced stages.
  • METHODS: Immunohistochemical staining with anti-p-Smad2 was performed on paraffin-embedded specimens from 135 patients with advanced gastric adenocarcinomas.
  • We also evaluated the relationship between the expression levels of p-Smad2 and clinicopathologic characteristics of patients with gastric adenocarcinomas.
  • RESULTS: The p-Smad2 expression level was high in 63 (47%) of 135 gastric carcinomas.
  • CONCLUSION: The expression of p-Smad2 is associated with malignant phenotype and poor prognosis in patients with advanced gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / chemistry. Peritoneal Neoplasms / chemistry. Smad2 Protein / analysis. Stomach Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2010 Mar 2;102(5):844-51 [20145621.001]
  • [Cites] Cancer Res. 2008 Nov 15;68(22):9107-11 [19010878.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):889-95 [11221876.001]
  • [Cites] Nat Genet. 2001 Oct;29(2):117-29 [11586292.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):497-505 [11809701.001]
  • [Cites] Cancer Sci. 2003 Mar;94(3):230-4 [12824914.001]
  • [Cites] Cancer J. 2003 Jul-Aug;9(4):302-12 [12967141.001]
  • [Cites] Nature. 2003 Oct 9;425(6958):577-84 [14534577.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8848-52 [14695201.001]
  • [Cites] Int J Cancer. 1989 Sep 15;44(3):394-8 [2777404.001]
  • [Cites] Br J Cancer. 1994 Apr;69(4):777-83 [8142266.001]
  • [Cites] Br J Cancer. 1996 Oct;74(7):1096-103 [8855981.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1803-4 [9351551.001]
  • [Cites] Mod Pathol. 1998 Feb;11(2):155-68 [9504686.001]
  • [Cites] Oncology. 1998 Nov-Dec;55(6):582-7 [9778627.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Cancer Sci. 2004 Nov;95(11):893-900 [15546507.001]
  • [Cites] Cancer Sci. 2005 Jul;96(7):451-5 [16053517.001]
  • [Cites] J Cell Sci. 2005 Aug 15;118(Pt 16):3573-84 [16105881.001]
  • [Cites] Genes Dev. 2005 Dec 1;19(23):2783-810 [16322555.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Feb;21(2):432-7 [16509870.001]
  • [Cites] J Surg Oncol. 2006 Jul 1;94(1):51-6 [16788944.001]
  • [Cites] Cancer Cell. 2007 Feb;11(2):147-60 [17292826.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3460-5 [17307870.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2850-60 [18451253.001]
  • [Cites] Cell. 2008 Jul 25;134(2):215-30 [18662538.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6B):4489-93 [11205293.001]
  • (PMID = 21110833.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / SMAD2 protein, human; 0 / Smad2 Protein
  • [Other-IDs] NLM/ PMC3001722
  •  go-up   go-down


92. Rhead JL, Letley DP, Mohammadi M, Hussein N, Mohagheghi MA, Eshagh Hosseini M, Atherton JC: A new Helicobacter pylori vacuolating cytotoxin determinant, the intermediate region, is associated with gastric cancer. Gastroenterology; 2007 Sep;133(3):926-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new Helicobacter pylori vacuolating cytotoxin determinant, the intermediate region, is associated with gastric cancer.
  • BACKGROUND & AIMS: Helicobacter pylori is the main cause of peptic ulceration and gastric adenocarcinoma.
  • Using a simple i-region polymerase chain reaction-based typing system, it was shown for 73 Iranian patients that i1-type strains were strongly associated with gastric adenocarcinoma (P < 10(-3)).
  • Finally, logistic regression analysis showed this association to be independent of, and larger than, associations of vacA s- or m-type or cag status with gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / microbiology. Bacterial Proteins / genetics. Helicobacter pylori / pathogenicity. Stomach Neoplasms / microbiology


93. Yakata Y, Nakayama T, Yoshizaki A, Kusaba T, Inoue K, Sekine I: Expression of p-STAT3 in human gastric carcinoma: significant correlation in tumour invasion and prognosis. Int J Oncol; 2007 Feb;30(2):437-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p-STAT3 in human gastric carcinoma: significant correlation in tumour invasion and prognosis.
  • Our aim was to determine the relationship between the expression of phosphorylated STAT3 (p-STAT3) and clinicopathological factors in human gastric adenocarcinoma.
  • One-hundred and eleven cases of surgically resected human gastric adenocarcinoma were studied by immunohistochemistry.
  • Moreover, expression of p-STAT3 was detected by Western blot analysis in 2 different kinds of cultured human gastric carcinoma cell lines and 4 cases of gastric carcinoma tissue obtained at surgery.
  • Constitutive activation of STAT3 may play an important role in the tumorigenesis of gastric adenocarcinoma, and the detailed mechanism of STAT3 signaling pathway in gastric adenocarcinoma deserves further investigation.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Gene Expression Regulation, Neoplastic. STAT3 Transcription Factor / biosynthesis. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17203226.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human
  •  go-up   go-down


94. Gül U, Gönül M, Soylu S, Heper AO, Demiriz M: An unusual occurrence of gastric adenocarcinoma in pemphigus vulgaris. Int J Dermatol; 2009 Sep;48(9):1018-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual occurrence of gastric adenocarcinoma in pemphigus vulgaris.
  • [MeSH-major] Adenocarcinoma / etiology. Pemphigus / complications. Stomach Neoplasms / etiology


95. Wronski M, Ziarkiewicz-Wroblewska B, Gornicka B, Cebulski W, Slodkowski M, Wasiutynski A, Krasnodebski IW: Synchronous occurrence of gastrointestinal stromal tumors and other primary gastrointestinal neoplasms. World J Gastroenterol; 2006 Sep 7;12(33):5360-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The synchronous stromal tumors were located in the stomach and were incidentally found during the operation.
  • The coexistent neoplasms were colon adenocarcinoma, gastric cancer (2 cases) and gastric lymphoma.
  • [MeSH-major] Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Stromal Tumors / diagnosis. Neoplasms, Second Primary / diagnosis

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2000 May;124(5):682-6 [10782147.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Sep;17(9):1033-6 [12167128.001]
  • [Cites] Med Sci Monit. 2004 Aug;10(8):LE13-4 [15278004.001]
  • [Cites] World J Gastroenterol. 2006 Feb 7;12(5):815-7 [16521203.001]
  • [Cites] Cancer. 1984 Mar 1;53(5):1088-92 [6692300.001]
  • [Cites] Nat Genet. 1998 Aug;19(4):323-4 [9697690.001]
  • [Cites] Mayo Clin Proc. 1999 Jun;74(6):543-52 [10377927.001]
  • [Cites] Pol J Pathol. 2005;56(2):51-61 [16092666.001]
  • [Cites] Cancer Res. 1970 Feb;30(2):455-65 [5458974.001]
  • (PMID = 16981268.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Other-IDs] NLM/ PMC4088205
  •  go-up   go-down


96. Ma XL, Sun HJ, Wang YS, Huang SH, Xie JW, Zhang HW: Study of Sonic hedgehog signaling pathway related molecules in gastric carcinoma. World J Gastroenterol; 2006 Jul 7;12(25):3965-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of Sonic hedgehog signaling pathway related molecules in gastric carcinoma.
  • AIM: To study the expression of Sonic hedgehog pathway-related molecules, Sonic hedgehog (Shh) and Gli1 in gastric carcinoma.
  • METHODS: Expression of Shh in 56 gastric specimens including non-cancerous gastric tissues, gastric adenocarcinoma, gastric squamous cell carcinoma was detected by RT-PCR, in situ hybridization and immunohistochemistry.
  • RESULTS: The positive rate of Shh and Gli1 expression was 0.0%, 0.0% in non-cancerous gastric tissues while it was 66.7%, 57.8% respectively in gastric adenocarcinoma, and 100%, 100% respectively in gastric squamous cell carcinoma.
  • There was a significant difference between the non-cancerous gastric tissues and gastric carcinoma (P<0.05).
  • Elevated expression of Shh and Gli1 in gastric tubular adenocarcinoma was associated with poorly differentiated tumors while the expression was absent in gastric mucinous adenocarcinoma.
  • CONCLUSION: The elevated expression of Shh and Gli1 in gastric adenocarcinoma and gastric squamous cell carcinoma shows the involvement of activated Shh signaling in the cellular proliferation of gastric carcinogenesis.
  • It suggests Shh signaling gene may be a new and good target gene for gastric tumor diagnosis and therapy.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Stomach Neoplasms / metabolism. Trans-Activators / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Hedgehog Proteins. Humans. RNA, Messenger / metabolism. Signal Transduction. Stomach / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Development. 2000 Jun;127(12):2763-72 [10821773.001]
  • [Cites] Cancer Lett. 2005 Sep 28;227(2):99-104 [16112412.001]
  • [Cites] Nat Immunol. 2001 Feb;2(2):172-80 [11175816.001]
  • [Cites] Genes Dev. 2001 Dec 1;15(23):3059-87 [11731473.001]
  • [Cites] Nat Neurosci. 2002 Feb;5(2):103-10 [11788837.001]
  • [Cites] Nature. 2002 Aug 22;418(6900):892-7 [12192414.001]
  • [Cites] Science. 2002 Aug 30;297(5586):1559-61 [12202832.001]
  • [Cites] Gut. 2002 Nov;51(5):628-33 [12377798.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):313-7 [12629553.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Lab Invest. 2003 Dec;83(12):1829-37 [14691301.001]
  • [Cites] Nature. 1996 Oct 3;383(6599):407-13 [8837770.001]
  • [Cites] Nat Genet. 1998 Sep;20(1):58-61 [9731532.001]
  • [Cites] Neuron. 1999 Jan;22(1):103-14 [10027293.001]
  • [Cites] J Mol Med (Berl). 1999 Jun;77(6):459-68 [10475061.001]
  • [Cites] Mol Cell Biol. 2000 Dec;20(23):9055-67 [11074003.001]
  • (PMID = 16810741.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / GLI1 protein, human; 0 / Hedgehog Proteins; 0 / RNA, Messenger; 0 / SHH protein, human; 0 / Trans-Activators; 0 / Transcription Factors
  • [Other-IDs] NLM/ PMC4087703
  •  go-up   go-down


97. Sjödahl K, Jia C, Vatten L, Nilsen T, Hveem K, Lagergren J: Salt and gastric adenocarcinoma: a population-based cohort study in Norway. Cancer Epidemiol Biomarkers Prev; 2008 Aug;17(8):1997-2001
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salt and gastric adenocarcinoma: a population-based cohort study in Norway.
  • BACKGROUND: Gastric adenocarcinoma is the second leading cause of cancer death worldwide.
  • It has been suggested that consumption of salted foods is associated with increased risk of this cancer, but the results of the few available prospective studies are contradictory.
  • METHODS: A population-based, prospective cohort study in Nord-Trondelag County in Norway during 1984 to 2002 addressed dietary salt intake in relation to risk of gastric adenocarcinoma.
  • Gastric adenocarcinomas were identified in the Norwegian Cancer Registry.
  • RESULTS: Follow-up of 1,122,765 person-years at risk among 73,133 cohort members disclosed 313 incident cases of gastric adenocarcinomas occurring at least 3 years after inclusion into the cohort.
  • There were no statistically significant associations between different levels of salt intake and risk of gastric adenocarcinoma.
  • High consumers of dietary salt were not at increased risk of developing gastric adenocarcinoma compared with low consumers (hazard ratio, 1.0; 95% confidence interval, 0.7-1.4), and no dose-response effect was observed (P(trend) = 0.55).
  • CONCLUSION: High intake of dietary salt does not appear to increase the risk of gastric adenocarcinoma in this low-incidence western population.
  • [MeSH-major] Adenocarcinoma / epidemiology. Sodium Chloride, Dietary. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Sodium.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18708389.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Sodium Chloride, Dietary
  •  go-up   go-down


98. Pandit R, Danilova IA: A case of atypical gastric carcinoma with osteoclast like giant cells. Mcgill J Med; 2008 Jul;11(2):152-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of atypical gastric carcinoma with osteoclast like giant cells.
  • Out of all the different types of neoplasms affecting the stomach, gastric carcinomas with Osteoclast-like Giant Cells (OGC) is one of the most uncommon.
  • Further examinations including endoscopy and biopsy of the stomach revealed gastric adenocarcinoma with OGC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 2007 Mar-Apr;27(2):785-91 [17465203.001]
  • [Cites] Anticancer Res. 2005 Sep-Oct;25(5):3629-36 [16101192.001]
  • [Cites] Arq Gastroenterol. 2005 Jan-Mar;42(1):30-4 [15976908.001]
  • [Cites] J Korean Med Sci. 2005 Jun;20(3):516-20 [15953882.001]
  • [Cites] Histopathology. 2001 Feb;38(2):111-9 [11207824.001]
  • [Cites] Am J Gastroenterol. 1999 Jun;94(6):1678-81 [10364044.001]
  • [Cites] Anticancer Res. 1998 Nov-Dec;18(6B):4699-704 [9891543.001]
  • [Cites] Am J Pathol. 1991 Sep;139(3):469-74 [1653517.001]
  • [Cites] Histopathology. 1999 Jun;34(6):502-9 [10383694.001]
  • (PMID = 19148314.001).
  • [ISSN] 1201-026X
  • [Journal-full-title] McGill journal of medicine : MJM : an international forum for the advancement of medical sciences by students
  • [ISO-abbreviation] Mcgill J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2582658
  • [Keywords] NOTNLM ; Osteoclast like Giant Cells (OGC) / adeno-carcinoma
  •  go-up   go-down


99. Bones J, Mittermayr S, O'Donoghue N, Guttman A, Rudd PM: Ultra performance liquid chromatographic profiling of serum N-glycans for fast and efficient identification of cancer associated alterations in glycosylation. Anal Chem; 2010 Dec 15;82(24):10208-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultra performance liquid chromatographic profiling of serum N-glycans for fast and efficient identification of cancer associated alterations in glycosylation.
  • Alterations in glycosylation have been noted in a number of diseases including cancer.
  • In the current study, the significant improvements in efficiency, selectivity, and analysis speed offered by ultra performance liquid chromatography (UPLC) profiling of fluorescently labeled N-linked oligosaccharides on a recently introduced sub-2 μm hydrophilic interaction (HILIC) based stationary phase are demonstrated to identify cancer associated alterations in the serum N-glycome of patients bearing stomach adenocarcinoma.
  • Alterations in the glycosylation present on these four proteins isolated from the pathologically staged cancer serum using either affinity purification or two-dimensional electrophoresis were then investigated as possible markers for stomach cancer progression.
  • [MeSH-minor] Adenocarcinoma. Humans. Protein Processing, Post-Translational. Stomach Neoplasms

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21073175.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Polysaccharides
  •  go-up   go-down


100. Athanassiou E, Vamvakopoulou DN, Zacharoulis D, Paroutoglou G, Sioutopoulou D, Tepetes K, Nomikos I, Vamvakopoulos NC: Immunophenotypic evaluation of DNA mismatch repair markers in 2 cases of synchronous histomorphologically distinct gastric adenocarcinomas with gastrointestinal stromal tumors of the proximal small bowel. Appl Immunohistochem Mol Morphol; 2010 May;18(3):288-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic evaluation of DNA mismatch repair markers in 2 cases of synchronous histomorphologically distinct gastric adenocarcinomas with gastrointestinal stromal tumors of the proximal small bowel.
  • OBJECTIVES: To assess the prognostic value of combined mismatch DNA repair (MMR) phenotyping in 2 synchronous histomorphologically distinct gastric adenocarcinomas (GADCs), each accompanied by gastrointestinal stromal tumors (GISTs) of the proximal small bowel.

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20090515.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / MLH1 protein, human; 0 / Nuclear Proteins; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down






Advertisement